幽门螺杆菌感染对颈动脉粥样硬化斑块的影响及TLR2在其脂多糖促泡沫细胞形成中的作用
|
摘要
炎症反应在动脉粥样硬化的发病和进展过程中起关键作用，其中感染引起的炎症反应与动脉粥样硬化的关系日益受到重视。最新的研究认为幽门螺杆菌（Helicobacterpylori，Hp）、肺炎衣原体、巨细胞病毒、单纯疱疹病毒等病原微生物感染是动脉粥样硬化的重要致病因素之一，其中Hp感染与动脉粥样硬化性疾病的相关性研究是近年来的热点。但是，目前国内外的研究多局限于Hp促动脉粥样硬化现象的观察和描述，缺少相关机制研究，Hp是如何促进动脉粥样硬化发展的机制尚不清楚。Hp属革兰阴性杆菌，脂多糖（LPS）是革兰阴性菌的重要致病因素。根据“动脉粥样硬化即炎性病变”的理论，Hp的感染及其LPS所诱发的炎症和免疫反应在动脉粥样硬化的发展中可能起到更重要的作用。
本研究分为以下几个方面：（1）人体水平：对动脉粥样硬化患者行颈动脉彩超观察斑块大小、性质及颈动脉内膜中层厚度（CIMT），收集颈动脉粥样硬化患者血清行Hp抗体及与动脉粥样硬化稳定性相关的炎症因子检测；（2）病理水平：对有手术指针患者行颈动脉内膜剥脱术（CEA），取得粥样硬化斑块切片免疫组化染色观察Hp感染患者粥样硬化斑块结构及炎症因子表达的变化；（3）细胞水平：通过Hp LPS干预RAW264.7巨噬细胞，观察Hp LPS对巨噬细胞吞噬氧化低密度脂蛋白的影响和释放炎症因子的变化；（4）膜受体水平：通过基因敲除动物，明确Hp LPS对巨噬细胞造成影响相关的Toll样受体类型。通过本研究明确幽门螺杆菌感染对颈动脉粥样硬化斑块稳定性的影响及Hp LPS在促进动脉粥样硬化中的作用机制，为动脉粥样硬化的发病机制提供新的视角，为脑卒中的预防提供新的理论依据和防治策略。
第一部分
幽门螺杆菌感染对颈动脉粥样硬化超声形态及血清炎症因子的影响
目的：在本实验通过检测动脉粥样硬化患者颈动脉彩超和血清MPO、MMP-9、LP-PLA2，观察幽门螺杆菌感染对动脉粥样硬化斑块形态、CIMT及血清炎症因子的影响。分析Hp感染对动脉粥样硬化斑块稳定性的影响，探讨其感染导致颈动脉粥样硬化形成的可能机制
方法：选择2011年4月到2011年9月在我院行颈动脉彩超提示动脉粥样硬化的知情同意者141例，其中男患者85例，女患者56例。行血清幽门螺杆菌抗体（Hp IgG）检测，根据患者血清幽门螺杆菌抗体结果分为幽门螺杆菌阳性组和幽门螺杆菌阴性组。进行血清幽门螺杆菌抗体（Hp-IgG）检测，颈总动脉内膜中层厚度检测，颈动脉粥样斑块形态的检测和血清MPO、MMP-9、LP-PLA2的检测。
结果：1. Hp阳性组颈动脉不稳定斑块29个，其中软斑24个，溃疡斑块5个；稳定斑块43个，其中扁平斑块26个，硬斑17个。Hp阴性组颈动脉不稳定斑块17个，其中软斑14个，溃疡斑块3个；稳定斑块52个，其中扁平斑块38个，硬斑14个。同Hp阴性组相比，Hp阳性组患者的不稳定性斑块发生率增高，并有统计学差异（P=0.0477）。2.通过颈动脉超声观察各组患者双侧颈总动脉CIMT, Hp阳性组左侧颈总动脉CIMT为0.096±0.0013，Hp阴性组左侧颈动脉CIMT为0.087±0.0019，阳性组较阴性组的左侧颈总动脉CIMT有显著增厚（P=0.0003）。Hp阳性组右侧颈总动脉CIMT为0.093±0.0011，Hp阴性组右侧颈动脉CIMT为0.086±0.0021，阳性组较阴性组的右侧颈总动脉CIMT有显著增厚（P=0.0041）。3. Hp阳性组血清MPO浓度为767.6±11.06ng/ml，较Hp阴性组707.2±15.38ng/ml显著增加（P=0.0017）。Hp阳性组血清hs-CRP浓度为4.257±1.102mg/dl，较Hp阴性组4.408±1.174mg/dl无显著差异。（P=0.0925）。Hp阳性组血清MPO浓度为21.40±0.2639ng/ml，较Hp阴性组19.80±0.4886ng/ml显著增加（P=0.0041）。Hp阳性组血清LP-PLA2浓度为393.8±4.855ng/ml，较Hp阴性组366.7±9.113ng/ml显著增加（P=0.0090）。
结论：1.本研究通过临床证实，Hp感染可引起动脉粥样硬化斑块不稳定性增加。2.Hp感染的动脉粥样硬化患者血清MPO、MMP-9、LP-PLA2增高，而hs-CRP增高不显著。
第二部分
幽门螺杆菌感染者颈动脉粥样硬化斑块结构分析及炎症因子表达的变化
目的：为了明确幽门螺杆菌感染者颈动脉粥样硬化斑块内炎症因子表达的变化，本实验通过对有手术指针的患者行CEA手术获得颈动脉粥样硬化斑块组织进行病理检测，行HE及免疫组化染色，观察其形态及炎症因子的表达与幽门螺杆菌感染的关系。
方法：从第一部分所研究的141例对象中，选择符合行颈动脉内膜切除术（carotidendarterectomy, CEA）的36例患者行CEA手术。Real-Time PCR检测颈动脉粥样斑块组织内炎症因子的mRNA变化，免疫组化检测颈动脉粥样硬化斑块组织的炎症因子表达。
结果：1. Real-time PCR结果显示Hp阳性组MPO的mRNA的相对GAPDH的表达量为3.096±0.2846，较Hp阴性组1.924±0.2535显著升高（P=0.0051）；Hp阳性组MMP-9的mRNA的相对GAPDH的表达量为2.212±0.3147，较Hp阴性组1.406±0.1907显著升高（P=0.0472）；Hp阳性组LP-PLA2的mRNA的相对GAPDH的表达量为7.013±0.9494，较Hp阴性组3.614±0.8607显著升高。2、Hp阳性组纤维帽厚度92.10±11.26μm，Hp阴性组纤维帽厚度130.9±12.43μm，Hp阴性组较阳性组纤维帽厚度明显增厚（P=0.0269）。Hp阳性组脂质池面积比为0.6172±0.03054， Hp阴性组脂质池面积比为0.5324±0.03702，Hp阳性组较阴性组脂质池面积增加，但差异不显著（P=0.0836）。3、同Hp阴性组相比较Hp阳性组动脉粥样硬化板块中的LP-PLA2、MPO、MMP-9表达均有明显增高。
结论：1.进一步证实，同不伴有Hp感染者相比，Hp感染者患颈动脉粥样硬化的危险性更大。2.Hp感染可能通过增强粥样硬化斑块局部的炎症反应及免疫反应促进和加重颈动脉粥样硬化形成。3. Hp感染者颈动脉粥样硬化局部炎症因子释放增多，从而影响颈动脉粥样硬化的形成。
第三部分
幽门螺杆菌脂多糖对巨噬细胞的影响
目的：因此为了明确幽门螺杆菌的在促动脉粥样硬化中的作用机制，本研究利用提纯的幽门螺杆菌脂多糖干预体外培养的巨噬细胞，观察巨噬细胞吞噬氧化低密度脂蛋白的变化以及释放的炎症因子改变。
方法提取和纯化幽门螺杆菌脂多糖，干扰培养的RAW264.7单核巨噬细胞，通过荧光探针Dil、油红O染色、酶荧光法定量观察巨噬细胞吞噬ox-LDL能力变化，并检测IL-6、TNF-α的mRNA观察巨噬细胞炎症因子释放情况，同时检测TLR2、TLR4的mRNA观察巨噬细胞受体的改变。
结果：1、可见加入Hp LPS组的巨噬细胞荧光明显增加，表明其吞噬的ox-LDL增加， ox-LDL+Hp LPS组巨噬细胞内胆固醇脂（CE）与较ox-LDL组明显增加（P=0.0023）。2、Real-time PCR结果显示不同时间Hp LPS刺激后，巨噬细胞的IL-6及TNF-α的mRNA变化趋势，其中以2-4小时变化最为显著(P<0.05)。3、当给予不同梯度稀释的Hp LPS刺激巨噬细胞后，其TLR2受体mRNA水平有上升趋势（P<0.01），而TLR4的mRNA水平则上升趋势不显著（P>0.05）。
结论：本研究通过提纯幽门螺杆菌脂多糖，并用其干预体外培养的RAW264.7单核巨噬细胞，发现巨噬细胞吞噬ox-LDL增加，促进了巨噬细胞向泡沫细胞转变，并引起巨噬细胞释放IL-1β、IL-6、TNF-α和MMP-9的增加。同时还观察到幽门螺杆菌脂多糖可促进巨噬细胞表面TLR2受体的表达增加，表明幽门螺杆菌脂多糖可能通过TLR2促进巨噬细胞向泡沫细胞转变及释放炎症介质。
第四部分TLR2基因敲除对Hp LPS促巨噬细胞泡沫化的影响
目的：通过Hp LPS干预TLR2基因敲除小鼠和C57BL/6J小鼠的腹腔巨噬细胞，检测其吞噬ox-LDL的变化以及TLR2、TLR4、胆固醇代谢受体和炎症因子的表达变化，明确Hp LPS作用于巨噬细胞的受体及探讨其促进巨噬细胞泡沫化的机制。
方法：分别取C57BL/6J小鼠和TLR2基因敲除小鼠的腹腔巨噬细胞，给予（Dil-）ox-LDL、（Dil-）ox-LDL+Hp LPS、（Dil-）ox-LDL、（Dil-）ox-LDL+Hp LPS处理。通过荧光探针Dil、酶荧光法定量观察巨噬细胞吞噬ox-LDL能力变化。并检测巨噬细胞IL-6、TNF-α的mRNA变化和巨噬细胞TLR受体及胆固醇代谢受体检测巨噬细胞CD36和ABCG1的mRNA变化。
结果：1、从荧光显像可见TLR2两组细胞荧光密度均较C57组降低，说明TLR2-/-小鼠腹腔巨噬细胞吞噬氧化低密度脂蛋白能力较C57小鼠吞噬能力降低。2、结果显示ox-Hp LPS组巨噬细胞内胆固醇脂（CE）与较ox-LDL组明显增加（P=0.0023）。3、Real-time PCR结果显示C57小鼠巨噬细胞受Hp LPS刺激后IL-6及TNF-α的mRNA变化较TLR2敲除小鼠明显增加。4、结果显示Hp LPS刺激后ABCG1的mRNA下降，而CD36的mRNA水平上调。其中LPS+LDL组与LDL组比较有显著差异（P<0.05）。
结论：1、Hp LPS可通过TLR2促进巨噬细胞吞噬ox-LDL，并促进其释放炎症介质2、Hp LPS可通过TLR2可促进ABCG1的mRNA下降，而CD36的mRNA水平上调。3、Hp LPS可能激活了PPARγ通路促进CD36的高表达，使巨噬细胞吞噬氧化低密度脂蛋白能力增加，同时抑制了LXRα通路，导致ABCG1低表达，使巨噬细胞胆固醇流出减少，两者协同作用，促进了动脉粥样硬化的发展。
The inflammatory response plays a key role in the incidence and progression ofatherosclerosis, in which infection-induced inflammation and atherosclerosis relationshiphave received increasing attention. The latest studies suggest that Helicobacter pylori (Hp),Chlamydia pneumoniae, cytomegalovirus, herpes simplex virus infection of pathogenicmicroorganisms is one of the important risk factors for atherosclerosis, in which Hpinfection and atherosclerosis sclerosing disease is a hot topic in recent years. However,studies at domestic and international was restricted to observation and description of thephenomena that Hp promote atherosclerosis, lacking of mechanisms study. How Hppromote the development of atherosclerosis mechanism is still unclear. Hp is a type ofGram-negative bacteria, lipopolysaccharide (LPS) is an important pathogenic factor ofGram-negative bacteria. According the theory "atherosclerosis is an inflammatory disease"we conclude that Hp infection and LPS-induced inflammation and immune response mayplay a more important role in the development of atherosclerosis.
The study is divided into the following aspects:(1)The body level: ultrasonographyobserve the size, nature and the carotid artery intima-media thickness (CIMT) of plaque incarotid atherosclerosis patients. Collect serum of carotid atherosclerosis patients and detectof Hp antibody and inflammatory factors related to the stability of atherosclerotic;(2) Thepathology level: obtain the atherosclerotic plaques by carotid endarterectomy surgery(CEA). Observe the changes in atherosclerotic plaque structure and expression ofinflammatory cytokines by immunohistochemical stained;(3) The cellular level: StimulateRAW264.7macrophages with Hp LPS, and observe the change of macrophagephagocytosis of oxidized low-density lipoprotein and the release of inflammatory factorsunder the influence of Hp LPS;(4) membrane receptor level: Through the knockoutanimals, clarify the type of Toll-like receptor on macrophages stimulated by Hp LPS. Thisstudy clarified the impact of Helicobacter pylori infection to carotid atherosclerotic plaquestability and the mechanism of Hp LPS promoting atherosclerosis. The stydy not onlyoffered new perspective for pathogenesis of atherosclerosis, but also offered newtheoretical basis and control strategies for stroke prevention.
PART Ⅰ The Impact of Helicobacter Pylori Infection on UltrasoundMorphology of Carotid Atherosclerosis and SerumInflammatory Cytokines
Objective: In this experiment, we observed the impact of H. pylori infection onarterial atherosclerotic plaque morphology, CIMT and serum inflammatory cytokines, bydetecting arterial atherosclerosis in patients with carotid ultrasound and serum MPO,MMP-9, LP-PLA2dencity, Analysis of Hp infection on atherosclerotic plaque stability,and to explore its possible mechanisms of infection lead to carotid artery atherosclerosis
Methods:141cases of carotid artery ultrasonography in our hospital from April2011to September2011prompted atherosclerosis informed consent,85cases were malepatients,56cases of female patients. Line serum Helicobacter pylori (Hp IgG) weredetected in patients with Helicobacter pylori antibody results into the H. pylori-positivegroup and the H. pylori-negative group. Serum Helicobacter pylori antibodies (Hp-IgG)testing, carotid artery intima-media thickness detection, detection of carotid artery plaquemorphology and serum of MPO and MMP-9, LP-PLA2detected.
Results:1.29unstable carotid plaque in Hp-positive group, including24soft plaquesand5ulcer plaques;43stable plaques, including flat plaques26and17hard plaques.17unstable carotid plaques in Hp-negative group, including14soft plaques and3ulcersplaques;52stable plaques, including38flat plaques and14hard plaques. WithHp-negative group compared to the Hp positive group of patients with unstable plaqueincidence increased, and there is a significant difference (P=0.0477).2. Observed throughthe carotid artery ultrasound Hp-positive group of patients in each group of bilateralcommon carotid artery CIMT values of the left common carotid artery CIMT value of0.096±0.0013, Hp-negative group, the left common carotid artery CIMT value of0.087±0.0019, positive group than in the negative The left common carotid artery CIMT groupsignificantly thicker (P=0.0003). Hp-positive group right common carotid artery CIMTvalue of0.093±0.0011, Hp-negative group, the right common carotid artery CIMT valueof0.086±0.0021, the positive group than negative group, the right common carotid arteryCIMT was significantly thickened (P=0.0041).3.Serum MPO concentration ofHp-positive group was767.6±11.06ng/ml compared to Hp-negative group,707.2±15.38ng/ml a significant increase (P=0.0017). Serum hs-CRP concentrations ofHp-positive group was4.257±1.102mg/dL, compared with Hp-negative group,4.408± 1.174mg/dl no significant difference.(P=0.0925). Hp-positive serum MPO concentrationof21.40±.2639ng/ml compared to Hp-negative group,19.80±0.4886ng/ml asignificant increase (P=0.0041). Hp-positive serum LP-of PLA2concentration was393.8±4.855ng/ml compared to Hp-negative group366.7±9.113ng/ml, a significantincrease (P=0.0090).
Conclusion:1. In this study, confirmed by clinical, atherosclerotic plaque instability beincreased caused by Hp infection.2. Artery atherosclerosis patients serum MPO, MMP-9and LP-PLA2but not hs-CRP increased with Hp infection.
PART Ⅱ Helicobacter Pylori infection and Carotid AtheroscleroticPlaque Results Changes of Structure and Expression ofInflammatory Cytokines
Objective: In order to clarify Helicobacter pylori infection and carotid atheroscleroticplaque inflammation factors expression changes，this experiment treated surgery pointerpatients with CEA surgery.And we made pathological examination in atheroscleroticplaque tissue, by HE and immunohistochemical staining, to observe the morphology andthe expression of inflammatory factors.
Methods:141cases from the first part of the research object,36patients of witchunderwent CEA surgery. Real-Time PCR detection of carotid atherosclerotic plaque withinthe organization of inflammatory factors mRNA, Immunohistochemical detection ofcarotid atherosclerotic plaques tissues, expression of inflammatory cytokines.
Results:1.The Real-time PCR results showed that Hp-positive group of MPO mRNArelative GAPDH expression level was3.096±0.2846, significantly higher compared toHp-negative group,1.924±0.2535(P=0.0051); Hp positive MMP-9mRNA relativeGAPDH expression level was2.212±0.3147, significantly higher than Hp-negative group1.406±0.1907(P=0.0472); Hp positive group LP-PLA2mRNA relative GAPDHexpression level was7.013±0.9494, were significantly increased compared to Hp-negativegroup (3.614±0.8607).2., fibrous cap thickness of the Hp positive group was92.10±11.26μm, fibrous cap thickness of the Hp-negative group was130.9±12.43μm. Hpnegative group’s fibrous cap thickness was significantly thicker than the positive group (P=0.0269). lipid pool area proportion of Hp positive group was0.6172±0.03054, lipidpool area proportion of the Hp negative group was0.5324±0.03702. lipid pool area increased in Hp-positive group, but the difference was not significant (P=0.0836).3.Hp-positive group of atherosclerotic plates in the LP-of PLA2, MPO and MMP-9expression were significantly increased compared with the Hp negative group.
Conclusions:1. Further confirmed, compared Hp negative group, Hp-infected personswere suffering from a greater risk of carotid atherosclerosis.2.Hp infection may enhancingthe atherosclerotic plaque inflammatory response and immune response and increasedcarotid artery atherosclerosis.3.Hp infected with carotid artery atherosclerosis localinflammatory factors increased, thus promoting the formation of carotid atherosclerosis.
PART Ⅲ Affection to Macrophages by Helicobacter PyloriLipopolysaccharide
Objective: In order to clarify the mechanism of H. pylori infection to promoteatherosclerosis, we intervented vitro cultured macrophages with purified H. pylorilipopolysaccharide. Observed macrophage phagocytosis of oxidized low-densitylipoprotein and release of inflammatory cytokines.
Methods: Interference cultured RAW264.7monocyte-macrophage cells with purifedHelicobacter pylori lipopolysaccharide. Observed tha change of macrophage phagocytosisox-LDL ability by fluorescent probes Dil, oil red O staining, enzyme fluorescent. Observerelease of macrophage inflammatory factor by detected IL-6, TNF-alpha mRNA, and at thesame time,we detect TLR2and TLR4mRNA to observe macrophage receptors.
Results:1.macrophage fluorescence was significantly increased stimulated by Hp LPS,indicating that the increase of the phagocytosis of ox-LDL. And the macrophagecholesteryl ester (CE) in ox-LDL+Hp LPS group was significantly increased comparedwith ox-LDL group (P=0.0023).2.Real-time PCR results showed that at different times ofHp LPS stimulation of macrophage IL-6and TNF-alpha mRNA trends, the mostsignificant change was2-4hours (P <0.05).3. When macrophages was stimulated bydifferent dilutions of Hp LPS, TLR2receptor mRNA levels is an upward trend (P <0.01),and TLR4mRNA level rise trend was not significant (P>0.05).
Conclusion: This study intervent vitro RAW264.7monocyte-macrophage cells bypurified H. pylori lipopolysaccharide.We found out that macrophage phagocytosis ofox-LDL increased, promoting the transformation of macrophages into foam cells, and cause macrophages release IL-6, TNF-alpha increased. Also observed that Helicobacterpylori lipopolysaccharide can promote the increase expression of TLR2receptors onmacrophage cell surface, indicating that H. pylori lipopolysaccharide may promote thetransformation of macrophages to foam cells and release of inflammatory mediatorsthrough TLR2.
Part Ⅳ Hp LPS Promote Macrophage Foam Cells Affected by TLR2Gene Knockout
Objective: Intervent peritoneal macrophages of the TLR2gene knock out mice andC57BL/6J mouse by Hp LPS,and detect changes in phagocytosis ox-LDL and TLR2/TLR4,cholesterol metabolism, receptors and inflammatory cytokines expression. Clarify Hp LPSeffect on macrophage receptors and to explore the mechanism of its catalytic macrophagefoam cells.
Methods: Lavage peritoneal macrophages from C57BL/6J and TLR2gene knock outmouse, dealed with（Dil-）ox-LDL、（Dil-）ox-LDL+Hp LPS、（Dil-）ox-LDL、（Dil-）ox-LDL+Hp LPS. Observed macrophage phagocytosis of ox-LDL ability by fluorescentprobe Dil, the statutory amount of the enzyme fluorescence. And detect IL-6, TNF-alphaand TLR receptors mRNA of macrophages and cholesterol metabolism in receptordetection macrophage CD36and of ABCG1mRNA.
Results:1.It can be seen from the fluorescence imaging that fluorescence intensitydecreased in TLR2-/-cells compared with the C57group, indicating that TLR2-/-mouseperitoneal macrophage phagocytic activity lower than C57mice.2.The results showed thatcholesteryl ester (CE) in macrophages of ox-Hp LPS group increased significantly thanox-LDL group.(P=0.0023).3. Real-time PCR results showed that the IL-6and TNF-alphamRNA of C57mice were significantly increased than the TLR2knockout mice stimulatedby Hp LPS.4. Real-time PCR results showed that ABCG1mRNA decreased, and CD36mRNA levels increase stimulated by Hp LPS, in which LPS+LDL group weresignificantly different with the LDL group (P <0.05).
Conclusion:1. Hp LPS can promote macrophage phagocytosis of ox-LDL, andrelease inflammatory mediators through TLR2.2. Hp LPS can promote ABCG1mRNAdecreased, with CD36mRNA levels increased through TLR.3. Hp LPS may activate PPARγ pathway to promote high expression of CD36, increased macrophage phagocytosisof oxidized LDL capacity, while inhibiting LXRα pathway, cause ABCG1low expression,and macrophage cholesterol efflux to reduce both coordination role in promoting thedevelopment of atherosclerosis.
本研究分为以下几个方面：（1）人体水平：对动脉粥样硬化患者行颈动脉彩超观察斑块大小、性质及颈动脉内膜中层厚度（CIMT），收集颈动脉粥样硬化患者血清行Hp抗体及与动脉粥样硬化稳定性相关的炎症因子检测；（2）病理水平：对有手术指针患者行颈动脉内膜剥脱术（CEA），取得粥样硬化斑块切片免疫组化染色观察Hp感染患者粥样硬化斑块结构及炎症因子表达的变化；（3）细胞水平：通过Hp LPS干预RAW264.7巨噬细胞，观察Hp LPS对巨噬细胞吞噬氧化低密度脂蛋白的影响和释放炎症因子的变化；（4）膜受体水平：通过基因敲除动物，明确Hp LPS对巨噬细胞造成影响相关的Toll样受体类型。通过本研究明确幽门螺杆菌感染对颈动脉粥样硬化斑块稳定性的影响及Hp LPS在促进动脉粥样硬化中的作用机制，为动脉粥样硬化的发病机制提供新的视角，为脑卒中的预防提供新的理论依据和防治策略。
第一部分
幽门螺杆菌感染对颈动脉粥样硬化超声形态及血清炎症因子的影响
目的：在本实验通过检测动脉粥样硬化患者颈动脉彩超和血清MPO、MMP-9、LP-PLA2，观察幽门螺杆菌感染对动脉粥样硬化斑块形态、CIMT及血清炎症因子的影响。分析Hp感染对动脉粥样硬化斑块稳定性的影响，探讨其感染导致颈动脉粥样硬化形成的可能机制
方法：选择2011年4月到2011年9月在我院行颈动脉彩超提示动脉粥样硬化的知情同意者141例，其中男患者85例，女患者56例。行血清幽门螺杆菌抗体（Hp IgG）检测，根据患者血清幽门螺杆菌抗体结果分为幽门螺杆菌阳性组和幽门螺杆菌阴性组。进行血清幽门螺杆菌抗体（Hp-IgG）检测，颈总动脉内膜中层厚度检测，颈动脉粥样斑块形态的检测和血清MPO、MMP-9、LP-PLA2的检测。
结果：1. Hp阳性组颈动脉不稳定斑块29个，其中软斑24个，溃疡斑块5个；稳定斑块43个，其中扁平斑块26个，硬斑17个。Hp阴性组颈动脉不稳定斑块17个，其中软斑14个，溃疡斑块3个；稳定斑块52个，其中扁平斑块38个，硬斑14个。同Hp阴性组相比，Hp阳性组患者的不稳定性斑块发生率增高，并有统计学差异（P=0.0477）。2.通过颈动脉超声观察各组患者双侧颈总动脉CIMT, Hp阳性组左侧颈总动脉CIMT为0.096±0.0013，Hp阴性组左侧颈动脉CIMT为0.087±0.0019，阳性组较阴性组的左侧颈总动脉CIMT有显著增厚（P=0.0003）。Hp阳性组右侧颈总动脉CIMT为0.093±0.0011，Hp阴性组右侧颈动脉CIMT为0.086±0.0021，阳性组较阴性组的右侧颈总动脉CIMT有显著增厚（P=0.0041）。3. Hp阳性组血清MPO浓度为767.6±11.06ng/ml，较Hp阴性组707.2±15.38ng/ml显著增加（P=0.0017）。Hp阳性组血清hs-CRP浓度为4.257±1.102mg/dl，较Hp阴性组4.408±1.174mg/dl无显著差异。（P=0.0925）。Hp阳性组血清MPO浓度为21.40±0.2639ng/ml，较Hp阴性组19.80±0.4886ng/ml显著增加（P=0.0041）。Hp阳性组血清LP-PLA2浓度为393.8±4.855ng/ml，较Hp阴性组366.7±9.113ng/ml显著增加（P=0.0090）。
结论：1.本研究通过临床证实，Hp感染可引起动脉粥样硬化斑块不稳定性增加。2.Hp感染的动脉粥样硬化患者血清MPO、MMP-9、LP-PLA2增高，而hs-CRP增高不显著。
第二部分
幽门螺杆菌感染者颈动脉粥样硬化斑块结构分析及炎症因子表达的变化
目的：为了明确幽门螺杆菌感染者颈动脉粥样硬化斑块内炎症因子表达的变化，本实验通过对有手术指针的患者行CEA手术获得颈动脉粥样硬化斑块组织进行病理检测，行HE及免疫组化染色，观察其形态及炎症因子的表达与幽门螺杆菌感染的关系。
方法：从第一部分所研究的141例对象中，选择符合行颈动脉内膜切除术（carotidendarterectomy, CEA）的36例患者行CEA手术。Real-Time PCR检测颈动脉粥样斑块组织内炎症因子的mRNA变化，免疫组化检测颈动脉粥样硬化斑块组织的炎症因子表达。
结果：1. Real-time PCR结果显示Hp阳性组MPO的mRNA的相对GAPDH的表达量为3.096±0.2846，较Hp阴性组1.924±0.2535显著升高（P=0.0051）；Hp阳性组MMP-9的mRNA的相对GAPDH的表达量为2.212±0.3147，较Hp阴性组1.406±0.1907显著升高（P=0.0472）；Hp阳性组LP-PLA2的mRNA的相对GAPDH的表达量为7.013±0.9494，较Hp阴性组3.614±0.8607显著升高。2、Hp阳性组纤维帽厚度92.10±11.26μm，Hp阴性组纤维帽厚度130.9±12.43μm，Hp阴性组较阳性组纤维帽厚度明显增厚（P=0.0269）。Hp阳性组脂质池面积比为0.6172±0.03054， Hp阴性组脂质池面积比为0.5324±0.03702，Hp阳性组较阴性组脂质池面积增加，但差异不显著（P=0.0836）。3、同Hp阴性组相比较Hp阳性组动脉粥样硬化板块中的LP-PLA2、MPO、MMP-9表达均有明显增高。
结论：1.进一步证实，同不伴有Hp感染者相比，Hp感染者患颈动脉粥样硬化的危险性更大。2.Hp感染可能通过增强粥样硬化斑块局部的炎症反应及免疫反应促进和加重颈动脉粥样硬化形成。3. Hp感染者颈动脉粥样硬化局部炎症因子释放增多，从而影响颈动脉粥样硬化的形成。
第三部分
幽门螺杆菌脂多糖对巨噬细胞的影响
目的：因此为了明确幽门螺杆菌的在促动脉粥样硬化中的作用机制，本研究利用提纯的幽门螺杆菌脂多糖干预体外培养的巨噬细胞，观察巨噬细胞吞噬氧化低密度脂蛋白的变化以及释放的炎症因子改变。
方法提取和纯化幽门螺杆菌脂多糖，干扰培养的RAW264.7单核巨噬细胞，通过荧光探针Dil、油红O染色、酶荧光法定量观察巨噬细胞吞噬ox-LDL能力变化，并检测IL-6、TNF-α的mRNA观察巨噬细胞炎症因子释放情况，同时检测TLR2、TLR4的mRNA观察巨噬细胞受体的改变。
结果：1、可见加入Hp LPS组的巨噬细胞荧光明显增加，表明其吞噬的ox-LDL增加， ox-LDL+Hp LPS组巨噬细胞内胆固醇脂（CE）与较ox-LDL组明显增加（P=0.0023）。2、Real-time PCR结果显示不同时间Hp LPS刺激后，巨噬细胞的IL-6及TNF-α的mRNA变化趋势，其中以2-4小时变化最为显著(P<0.05)。3、当给予不同梯度稀释的Hp LPS刺激巨噬细胞后，其TLR2受体mRNA水平有上升趋势（P<0.01），而TLR4的mRNA水平则上升趋势不显著（P>0.05）。
结论：本研究通过提纯幽门螺杆菌脂多糖，并用其干预体外培养的RAW264.7单核巨噬细胞，发现巨噬细胞吞噬ox-LDL增加，促进了巨噬细胞向泡沫细胞转变，并引起巨噬细胞释放IL-1β、IL-6、TNF-α和MMP-9的增加。同时还观察到幽门螺杆菌脂多糖可促进巨噬细胞表面TLR2受体的表达增加，表明幽门螺杆菌脂多糖可能通过TLR2促进巨噬细胞向泡沫细胞转变及释放炎症介质。
第四部分TLR2基因敲除对Hp LPS促巨噬细胞泡沫化的影响
目的：通过Hp LPS干预TLR2基因敲除小鼠和C57BL/6J小鼠的腹腔巨噬细胞，检测其吞噬ox-LDL的变化以及TLR2、TLR4、胆固醇代谢受体和炎症因子的表达变化，明确Hp LPS作用于巨噬细胞的受体及探讨其促进巨噬细胞泡沫化的机制。
方法：分别取C57BL/6J小鼠和TLR2基因敲除小鼠的腹腔巨噬细胞，给予（Dil-）ox-LDL、（Dil-）ox-LDL+Hp LPS、（Dil-）ox-LDL、（Dil-）ox-LDL+Hp LPS处理。通过荧光探针Dil、酶荧光法定量观察巨噬细胞吞噬ox-LDL能力变化。并检测巨噬细胞IL-6、TNF-α的mRNA变化和巨噬细胞TLR受体及胆固醇代谢受体检测巨噬细胞CD36和ABCG1的mRNA变化。
结果：1、从荧光显像可见TLR2两组细胞荧光密度均较C57组降低，说明TLR2-/-小鼠腹腔巨噬细胞吞噬氧化低密度脂蛋白能力较C57小鼠吞噬能力降低。2、结果显示ox-Hp LPS组巨噬细胞内胆固醇脂（CE）与较ox-LDL组明显增加（P=0.0023）。3、Real-time PCR结果显示C57小鼠巨噬细胞受Hp LPS刺激后IL-6及TNF-α的mRNA变化较TLR2敲除小鼠明显增加。4、结果显示Hp LPS刺激后ABCG1的mRNA下降，而CD36的mRNA水平上调。其中LPS+LDL组与LDL组比较有显著差异（P<0.05）。
结论：1、Hp LPS可通过TLR2促进巨噬细胞吞噬ox-LDL，并促进其释放炎症介质2、Hp LPS可通过TLR2可促进ABCG1的mRNA下降，而CD36的mRNA水平上调。3、Hp LPS可能激活了PPARγ通路促进CD36的高表达，使巨噬细胞吞噬氧化低密度脂蛋白能力增加，同时抑制了LXRα通路，导致ABCG1低表达，使巨噬细胞胆固醇流出减少，两者协同作用，促进了动脉粥样硬化的发展。
The inflammatory response plays a key role in the incidence and progression ofatherosclerosis, in which infection-induced inflammation and atherosclerosis relationshiphave received increasing attention. The latest studies suggest that Helicobacter pylori (Hp),Chlamydia pneumoniae, cytomegalovirus, herpes simplex virus infection of pathogenicmicroorganisms is one of the important risk factors for atherosclerosis, in which Hpinfection and atherosclerosis sclerosing disease is a hot topic in recent years. However,studies at domestic and international was restricted to observation and description of thephenomena that Hp promote atherosclerosis, lacking of mechanisms study. How Hppromote the development of atherosclerosis mechanism is still unclear. Hp is a type ofGram-negative bacteria, lipopolysaccharide (LPS) is an important pathogenic factor ofGram-negative bacteria. According the theory "atherosclerosis is an inflammatory disease"we conclude that Hp infection and LPS-induced inflammation and immune response mayplay a more important role in the development of atherosclerosis.
The study is divided into the following aspects:(1)The body level: ultrasonographyobserve the size, nature and the carotid artery intima-media thickness (CIMT) of plaque incarotid atherosclerosis patients. Collect serum of carotid atherosclerosis patients and detectof Hp antibody and inflammatory factors related to the stability of atherosclerotic;(2) Thepathology level: obtain the atherosclerotic plaques by carotid endarterectomy surgery(CEA). Observe the changes in atherosclerotic plaque structure and expression ofinflammatory cytokines by immunohistochemical stained;(3) The cellular level: StimulateRAW264.7macrophages with Hp LPS, and observe the change of macrophagephagocytosis of oxidized low-density lipoprotein and the release of inflammatory factorsunder the influence of Hp LPS;(4) membrane receptor level: Through the knockoutanimals, clarify the type of Toll-like receptor on macrophages stimulated by Hp LPS. Thisstudy clarified the impact of Helicobacter pylori infection to carotid atherosclerotic plaquestability and the mechanism of Hp LPS promoting atherosclerosis. The stydy not onlyoffered new perspective for pathogenesis of atherosclerosis, but also offered newtheoretical basis and control strategies for stroke prevention.
PART Ⅰ The Impact of Helicobacter Pylori Infection on UltrasoundMorphology of Carotid Atherosclerosis and SerumInflammatory Cytokines
Objective: In this experiment, we observed the impact of H. pylori infection onarterial atherosclerotic plaque morphology, CIMT and serum inflammatory cytokines, bydetecting arterial atherosclerosis in patients with carotid ultrasound and serum MPO,MMP-9, LP-PLA2dencity, Analysis of Hp infection on atherosclerotic plaque stability,and to explore its possible mechanisms of infection lead to carotid artery atherosclerosis
Methods:141cases of carotid artery ultrasonography in our hospital from April2011to September2011prompted atherosclerosis informed consent,85cases were malepatients,56cases of female patients. Line serum Helicobacter pylori (Hp IgG) weredetected in patients with Helicobacter pylori antibody results into the H. pylori-positivegroup and the H. pylori-negative group. Serum Helicobacter pylori antibodies (Hp-IgG)testing, carotid artery intima-media thickness detection, detection of carotid artery plaquemorphology and serum of MPO and MMP-9, LP-PLA2detected.
Results:1.29unstable carotid plaque in Hp-positive group, including24soft plaquesand5ulcer plaques;43stable plaques, including flat plaques26and17hard plaques.17unstable carotid plaques in Hp-negative group, including14soft plaques and3ulcersplaques;52stable plaques, including38flat plaques and14hard plaques. WithHp-negative group compared to the Hp positive group of patients with unstable plaqueincidence increased, and there is a significant difference (P=0.0477).2. Observed throughthe carotid artery ultrasound Hp-positive group of patients in each group of bilateralcommon carotid artery CIMT values of the left common carotid artery CIMT value of0.096±0.0013, Hp-negative group, the left common carotid artery CIMT value of0.087±0.0019, positive group than in the negative The left common carotid artery CIMT groupsignificantly thicker (P=0.0003). Hp-positive group right common carotid artery CIMTvalue of0.093±0.0011, Hp-negative group, the right common carotid artery CIMT valueof0.086±0.0021, the positive group than negative group, the right common carotid arteryCIMT was significantly thickened (P=0.0041).3.Serum MPO concentration ofHp-positive group was767.6±11.06ng/ml compared to Hp-negative group,707.2±15.38ng/ml a significant increase (P=0.0017). Serum hs-CRP concentrations ofHp-positive group was4.257±1.102mg/dL, compared with Hp-negative group,4.408± 1.174mg/dl no significant difference.(P=0.0925). Hp-positive serum MPO concentrationof21.40±.2639ng/ml compared to Hp-negative group,19.80±0.4886ng/ml asignificant increase (P=0.0041). Hp-positive serum LP-of PLA2concentration was393.8±4.855ng/ml compared to Hp-negative group366.7±9.113ng/ml, a significantincrease (P=0.0090).
Conclusion:1. In this study, confirmed by clinical, atherosclerotic plaque instability beincreased caused by Hp infection.2. Artery atherosclerosis patients serum MPO, MMP-9and LP-PLA2but not hs-CRP increased with Hp infection.
PART Ⅱ Helicobacter Pylori infection and Carotid AtheroscleroticPlaque Results Changes of Structure and Expression ofInflammatory Cytokines
Objective: In order to clarify Helicobacter pylori infection and carotid atheroscleroticplaque inflammation factors expression changes，this experiment treated surgery pointerpatients with CEA surgery.And we made pathological examination in atheroscleroticplaque tissue, by HE and immunohistochemical staining, to observe the morphology andthe expression of inflammatory factors.
Methods:141cases from the first part of the research object,36patients of witchunderwent CEA surgery. Real-Time PCR detection of carotid atherosclerotic plaque withinthe organization of inflammatory factors mRNA, Immunohistochemical detection ofcarotid atherosclerotic plaques tissues, expression of inflammatory cytokines.
Results:1.The Real-time PCR results showed that Hp-positive group of MPO mRNArelative GAPDH expression level was3.096±0.2846, significantly higher compared toHp-negative group,1.924±0.2535(P=0.0051); Hp positive MMP-9mRNA relativeGAPDH expression level was2.212±0.3147, significantly higher than Hp-negative group1.406±0.1907(P=0.0472); Hp positive group LP-PLA2mRNA relative GAPDHexpression level was7.013±0.9494, were significantly increased compared to Hp-negativegroup (3.614±0.8607).2., fibrous cap thickness of the Hp positive group was92.10±11.26μm, fibrous cap thickness of the Hp-negative group was130.9±12.43μm. Hpnegative group’s fibrous cap thickness was significantly thicker than the positive group (P=0.0269). lipid pool area proportion of Hp positive group was0.6172±0.03054, lipidpool area proportion of the Hp negative group was0.5324±0.03702. lipid pool area increased in Hp-positive group, but the difference was not significant (P=0.0836).3.Hp-positive group of atherosclerotic plates in the LP-of PLA2, MPO and MMP-9expression were significantly increased compared with the Hp negative group.
Conclusions:1. Further confirmed, compared Hp negative group, Hp-infected personswere suffering from a greater risk of carotid atherosclerosis.2.Hp infection may enhancingthe atherosclerotic plaque inflammatory response and immune response and increasedcarotid artery atherosclerosis.3.Hp infected with carotid artery atherosclerosis localinflammatory factors increased, thus promoting the formation of carotid atherosclerosis.
PART Ⅲ Affection to Macrophages by Helicobacter PyloriLipopolysaccharide
Objective: In order to clarify the mechanism of H. pylori infection to promoteatherosclerosis, we intervented vitro cultured macrophages with purified H. pylorilipopolysaccharide. Observed macrophage phagocytosis of oxidized low-densitylipoprotein and release of inflammatory cytokines.
Methods: Interference cultured RAW264.7monocyte-macrophage cells with purifedHelicobacter pylori lipopolysaccharide. Observed tha change of macrophage phagocytosisox-LDL ability by fluorescent probes Dil, oil red O staining, enzyme fluorescent. Observerelease of macrophage inflammatory factor by detected IL-6, TNF-alpha mRNA, and at thesame time,we detect TLR2and TLR4mRNA to observe macrophage receptors.
Results:1.macrophage fluorescence was significantly increased stimulated by Hp LPS,indicating that the increase of the phagocytosis of ox-LDL. And the macrophagecholesteryl ester (CE) in ox-LDL+Hp LPS group was significantly increased comparedwith ox-LDL group (P=0.0023).2.Real-time PCR results showed that at different times ofHp LPS stimulation of macrophage IL-6and TNF-alpha mRNA trends, the mostsignificant change was2-4hours (P <0.05).3. When macrophages was stimulated bydifferent dilutions of Hp LPS, TLR2receptor mRNA levels is an upward trend (P <0.01),and TLR4mRNA level rise trend was not significant (P>0.05).
Conclusion: This study intervent vitro RAW264.7monocyte-macrophage cells bypurified H. pylori lipopolysaccharide.We found out that macrophage phagocytosis ofox-LDL increased, promoting the transformation of macrophages into foam cells, and cause macrophages release IL-6, TNF-alpha increased. Also observed that Helicobacterpylori lipopolysaccharide can promote the increase expression of TLR2receptors onmacrophage cell surface, indicating that H. pylori lipopolysaccharide may promote thetransformation of macrophages to foam cells and release of inflammatory mediatorsthrough TLR2.
Part Ⅳ Hp LPS Promote Macrophage Foam Cells Affected by TLR2Gene Knockout
Objective: Intervent peritoneal macrophages of the TLR2gene knock out mice andC57BL/6J mouse by Hp LPS,and detect changes in phagocytosis ox-LDL and TLR2/TLR4,cholesterol metabolism, receptors and inflammatory cytokines expression. Clarify Hp LPSeffect on macrophage receptors and to explore the mechanism of its catalytic macrophagefoam cells.
Methods: Lavage peritoneal macrophages from C57BL/6J and TLR2gene knock outmouse, dealed with（Dil-）ox-LDL、（Dil-）ox-LDL+Hp LPS、（Dil-）ox-LDL、（Dil-）ox-LDL+Hp LPS. Observed macrophage phagocytosis of ox-LDL ability by fluorescentprobe Dil, the statutory amount of the enzyme fluorescence. And detect IL-6, TNF-alphaand TLR receptors mRNA of macrophages and cholesterol metabolism in receptordetection macrophage CD36and of ABCG1mRNA.
Results:1.It can be seen from the fluorescence imaging that fluorescence intensitydecreased in TLR2-/-cells compared with the C57group, indicating that TLR2-/-mouseperitoneal macrophage phagocytic activity lower than C57mice.2.The results showed thatcholesteryl ester (CE) in macrophages of ox-Hp LPS group increased significantly thanox-LDL group.(P=0.0023).3. Real-time PCR results showed that the IL-6and TNF-alphamRNA of C57mice were significantly increased than the TLR2knockout mice stimulatedby Hp LPS.4. Real-time PCR results showed that ABCG1mRNA decreased, and CD36mRNA levels increase stimulated by Hp LPS, in which LPS+LDL group weresignificantly different with the LDL group (P <0.05).
Conclusion:1. Hp LPS can promote macrophage phagocytosis of ox-LDL, andrelease inflammatory mediators through TLR2.2. Hp LPS can promote ABCG1mRNAdecreased, with CD36mRNA levels increased through TLR.3. Hp LPS may activate PPARγ pathway to promote high expression of CD36, increased macrophage phagocytosisof oxidized LDL capacity, while inhibiting LXRα pathway, cause ABCG1low expression,and macrophage cholesterol efflux to reduce both coordination role in promoting thedevelopment of atherosclerosis.
引文
1. International Carotid Stenting Study Investigators. Carotid artery stenting comparedwith endarterectomy in patients with symptomatic carotid stenosis (InternationalCarotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet.2010;375:985-97.
2. Brott TG, Hobson RW, Howard G, et al, for the CREST Investigator. Stenting versusEndarterectomy for Treatment of Carotid-Artery Stenosis. N Engl J Med.2010;363:11-23.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med.1999;340:115–126.
4. G ran K. Hansson. Inflammation, Atherosclerosis, and Coronary Artery Disease. NEngl J Med.2005;352:1685-95.
5. AndriéRP, Bauriedel G, Tuleta I, et al. Impact of intimal pathogen burden in acutecoronary syndromes--correlation with inflammation, thrombosis, and autoimmunity.Cardiovasc Pathol.2010;19(6):e205-10.
6. Farsak B, Yildirir A, Aky n Y, et al. Detection of Chlamydia pneumoniae andHelicobacter pylori DNA in Human Atherosclerotic Plaques by PCR. J Clin Microbiol.2000;38(12):4408-11.
7. Kaplan M, Yavuz SS, Cinar B, et al. Detection of Chlamydia pneumoniae andHelicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chainreaction. Int J Infect Dis.2006;10(2):116-23.
8. Kowalski M, Pawlik M, Konturek JW, et al. Helicobacter pylori infection in coronaryartery disease. J Physiol Pharmacol.2006;57Suppl3:101-11.
9. Elkind MS, Luna JM, Moon YP, et al. Infectious burden and carotid plaque thickness:the northern Manhattan study. Stroke.2010;41(3):e117-22.
10. Sawayama Y, Ariyama I, Hamada M, et al. Association between chronic Helicobacterpylori infection and acute ischemic stroke: Fukuoka Harasanshin Atherosclerosis Trial(FHAT). Atherosclerosis.2005;178(2):303-9.
11. Cremonini F, Gabrielli M, Gasbarrini G, et al. The relationship between chronic H.pylori infection, CagA seropositivity and stroke: meta-analysis. Atherosclerosis.2004;173,(2)：253-9.
12.耿学川,赵晓红,韩立荣.脑梗死患者幽门螺杆菌感染状况及其与血脂代谢的关系.神经损伤与功能重建.2010;1:24-6.
13.杨旭,耿学川,李继来,等.缺血性脑卒中患者幽门螺杆菌感染与超敏C反应蛋白相关性研究.中国神经免疫学和神经病学杂志.2010;1:46-8,51.
14.吕淼.幽门螺杆菌与动脉粥样硬化炎症因子相关性分析.现代医药卫生.2009;25(7):1029-30.
15.陶珍.幽门螺杆菌细胞毒素相关蛋白A阳性菌株感染与颈动脉粥样硬化形成的相关性及可能机制研究.第二军医大学博士学位论文.2009（.导师：丁素菊,曲乐丰）
16.陶珍,曲乐丰*,丁素菊,等.颈动脉粥样硬化斑块内幽门螺杆菌-细胞毒素相关蛋白A-IgG抗体的表达与颈动脉粥样硬化性脑梗死的关系.上海医学杂志.2009,32(4):296-8（*通讯作者）
17.陶珍,曲乐丰*,丁素菊,等.幽门螺杆菌感染致兔颈动脉粥样硬化模型的建立.第二军医大学学报,2010,31(1):37-41（*通讯作者）
18.贾庆帅,曲乐丰*,赵宝珍,陶珍.幽门螺杆菌感染致兔颈动脉粥样硬化模型的超声表现.上海医学,2010,33(8):757-60（*通讯作者）
1.中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010.中华神经科杂志.2010;43(2):146-153.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med.1999;340:115–126.
3. Grau AJ, Buggle F, Lichy C, et al. Helicobacter pylori infection as an independent risk factor forcerebral ischemia of atherothrombotic origin. J Neurol Sci.2001;186(1-2):1-5.
4. Mat hiesen EB，Bonaa KH，Joakimsen O．Echolucent plaques are associated with high risk ofischemic cerebrovascular events in carotid stenosis．Circulation.2001;103(17)：21-27.
5.吴莉娟.高频彩超对颈动脉粥样硬化的诊断价值.海南医学.2003;14,8.
6. Prelipcean CC, Mihai C, Gog lniceanu P, et al. Extragastric manifestations of Helicobacter pyloriinfection.Rev Med Chir Soc Med Nat Iasi.2007;111(3):575-583.
7. Franceschi F, Gasbarrini A.Helicobacter pylori and extragastric diseases. Best Pract Res ClinGastroenterol.2007;21(2):325-334.
8. Farsak B, Yildirir A, Aky n Y, et al. Detection of Chlamydia pneumoniae and Helicobacter pyloriDNA in Human Atherosclerotic Plaques by PCR. J Clin Microbiol.2000;38(12):4408-4411.
9. Elkind MS, Luna JM, Moon YP, et al. Infectious burden and carotid plaque thickness: the northernManhattan study. Stroke.2010;41(3):e117-122.
10. Sawayama Y, Ariyama I, Hamada M, et al. Association between chronic Helicobacter pyloriinfection and acute ischemic stroke: Fukuoka Harasanshin Atherosclerosis Trial (FHAT).Atherosclerosis.2005;178(2):303-309.
11. Cremonini F, Gabrielli M, Gasbarrini G, et al. The relationship between chronic H. pylori infection,CagA seropositivity and stroke: meta-analysis. Atherosclerosis.2004;173,(2):253-259.
12. Grau AJ, Buggle F, Lichy C, et al. Helicobacter pylori infection as an independent risk factor forcerebral ischemia of atherothrombotic origin. J Neurol Sci.2001;186(1-2):1-5.
13. Michiel L,Arno W, Peter J, et al. Common Carotid Intima-Media Thickness and Risk of Stroke andMyocardial Infarction-The Rotterdam Study.Circulation.1997;96:1432-1437.
14. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotidintima-media thickness: a systematic review and meta-analysis.Circulation.2007;115(4):459-467.
15. Mookadam F, Tanasunont W, Jalal U, Mookadam M, Wilansky S. Carotid intima-media thicknessand cardiovascular risk.Future Cardiol.2011;7(2):173-182.
16. Akbas HS, Basyigit S, Suleymanlar I, et al.The assessment of carotid intima media thickness andserum paraoxonase-1activity in Helicobacter pylori positive subjects. Lipids Health Dis.2010;9:92.
17.中国医师协会超声医师分会.血管超声检查指南.中华超声影像学杂志.2009;10:911-920.
18. Pasceri V, Patti G, Cammarota G, et al. Virulent strains of Helicobacter pylori and vascular diseases:a meta-analysis. Am Heart J.2006;151:1215–1222.
19. Sebastián F, Esteban A, Ramón C, et al. Detection of Helicobacter pylori in Human CarotidAtherosclerotic Plaques. Stroke.2001;32:385-391.
20. Ro ankovi PB, Huzjan AL, Cupi H, et al. Influence of CagA-positive Helicobacter pylori strainson atherosclerotic carotid disease.J Neurol.2011;258(5):753-761.
21. Cremonini F, Gabrielli M, Gasbarrini G, et al. The relationship between chronic H. pylori infection,CagA seropositivity and stroke: meta-analysis. Atherosclerosis.2004;173,(2):253-259.
22. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med.1999;340:115–126.
23. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarkerdiscovery and risk prediction.Clin Chem.2008;54(1):24-38.
24. Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: asystematic review. Stroke.2008;39(10):2902-2909.
25. Cojocaru IM, Cojocaru M, Iliescu I, et al. Plasma myeloperoxidase levels in patients with acuteischemic stroke. Rom J Intern Med.2010;48(1):101-104.
26. Wang CA, Liu YC, Du SY, et al. Helicobacter pylori neutrophil-activating protein promotesmyeloperoxidase release from human neutrophils. Biochem Biophys Res Commun.2008;377(1):52-56.
27. Nazligul Y, Aslan M, Horoz M, et al. The effect on serum myeloperoxidase activity and oxidativestatus of eradication treatment in patients Helicobacter pylori infected. Clin Biochem.2011;44(8-9):647-649.
28. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep.2004;6(2):112-120.
29. Mori N. Helicobacter pylori induces matrix metalloproteinase expression. Nippon Rinsho.2005;63Suppl11:138-145.
30. Kundu P, Mukhopadhyay AK, Patra R, et al. Cag pathogenicity island-independent up-regulationof matrix metalloproteinases-9and-2secretion and expression in mice by Helicobacter pyloriinfection. J Biol Chem.2006;281(45):34651-34662.
31. Rautelin HI, Oksanen AM, Veijola LI, Sipponen PI, Tervahartiala TI, Sorsa TA, LauhioA.Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis. Ann Med.2009;41(3):208-215.
32. Kountouras J, Zavos C, Deretzi G, et al. Helicobacter pylori may be involved in strokepathophysiology by altering tumor necrosis factor-α and matrix metalloproteinases. Eur J Neurol.2011;18(7).
33. Vittos O, Toana B, Vittos A, et al. Lipoprotein-associated phospholipase A2(Lp-PLA2): a reviewof its role and significance as a cardiovascular biomarker. Biomarkers.2012Mar9[Epub ahead ofprint].
34. Serruys PW，Heictor M，Garcia HM，et a1． Effects of the directlipoprotein-associatedphospholipase A2inhibitor darapladib onhuman coronary atherosclerotic plaque． Circulation，2008;118:1171-1182．
35. Libby P, Ridker P M, Maseri A, et al. Inflammation and Atherosclerosis. Circulation.2002;105:1135
36. Corrado E, Rizzo M, Tantillo R.,et al. Markers of inflammation and infection influence theoutcome of patients with baseline asymptomatic carotid lesions: a5-year follow-up study. Stroke.2006;37(2):482-486.
37. Jafarzadeh A, Hassanshahi GH, Nemati M, et al. Serum levels of high-sensitivity C-reactiveprotein (hs-CRP)in Helicobacter pylori-infected peptic ulcer patients and its association withbacterial CagA virulence factor.Dig Dis Sci.2009;54(12):2612-2616.
38. El-Mashad N, El-Emshaty WM, Arfat MS,et al. Relation of Cag-A-positive Helicobacter pyloristrain and some inflammatory markers in patients with ischemic heart diseases. Egypt J Immunol.2009;16(1):39-47.
39. Kebapcilar L, Bilgir O, Cetinkaya E, et al. The effect of Helicobacter pylori eradication onmacrophage migration inhibitory factor, C-reactive protein and fetuin-a levels. Clinics (Sao Paulo).2010;65(8):799-802.
1. Farsak B, Yildirir A, Aky n Y, et al. Detection of Chlamydia pneumoniae and Helicobacter pyloriDNA in Human Atherosclerotic Plaques by PCR. J Clin Microbiol.2000Dec;38(12):4408-11.
2. Kaplan M, Yavuz SS, Cinar B, et al. Detection of Chlamydia pneumoniae and Helicobacter pyloriin atherosclerotic plaques of carotid artery by polymerase chain reaction. Int J Infect Dis.2006Mar;10(2):116-23.
3. Casscells W, Naghavi M, Willerson JT. Vulnerable Atherosclerotic Plaque：A Multifocal Disease.Circulation.2003;107:2072-75
4. Innocenti M, Svennerholm AM, Quiding-J rbrink M. Helicobacter pylori lipopolysaccharidespreferentially induce CXC chemokine production in human monocytes. Infect Immun.2001Jun;69(6):3800-8.
5. M. Madjid, M. Ali, J.T. Willerson. Lipoprotein-associated phospholipase A2as a novel risk markerfor cardiovascular disease: a systematic review of the literature. Tex Heart Inst J,37(2010), pp.25–39
6. Z. Mallat, G. Lambeau, A. Tedgui. Lipoprotein-associated and secreted phospholipases A2incardiovascular disease: roles as biological effectors and biomarkers. Circulation,122(2010), pp.2183–2200
7. M.H. Davidson, M.A. Corson, M.J. Alberts, et al. Consensus panel recommendation forincorporating lipoprotein-associated phospholipase A2testing into cardiovascular disease riskassessment guidelines. Am J Cardiol,101(2008), pp.51F–57F
8. Hazen SL, Heinecke JW.3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzedoxidation, is markedly elevated in low density lipoprotein isolated from human atheroscleroticintima. J Clin Invest.1997;99:2075–2081.
9. Watanabe N, Ikeda U. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep.2004Mar;6(2):112-20.
10. Beaudeux JL, Giral P, Bruckert E. Matrix metalloproteinases, inflammation and atherosclerosis:therapeutic perspectives. Clin Chem Lab Med.2004Feb;42(2):121-31.
11.刘龙斌,郭航远,池菊芳.基质金属蛋白酶在动脉粥样硬化中的研究进展.中国全科医学,2009，12(7A):1232-4.
12. W gs ter D, Zhu C, Bj rkegren J, et al. MMP-2and MMP-9are prominent matrixmetalloproteinases during atherosclerosis development in the Ldlr-/-Apob100/100mouse. Int JMol Med.2011Aug;28(2):247-53.
13. Mori N. Helicobacter pylori induces matrix metalloproteinase expression. Nippon Rinsho.2005Nov;63Suppl11:138-45.
14. Kundu P, Mukhopadhyay AK, Patra R, et al. Cag pathogenicity island-independent up-regulationof matrix metalloproteinases-9and-2secretion and expression in mice by Helicobacter pyloriinfection. J Biol Chem.2006Nov10;281(45):34651-62.
15. Rautelin HI, Oksanen AM, Veijola LI, Sipponen PI, Tervahartiala TI, Sorsa TA, LauhioA.Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.Ann Med.2009;41(3):208-15.
1.易光辉.动脉粥样硬化.中国动脉硬化杂志.2005,1:96-96.
2. MacRae F, Sergio F. Macrophages, inflammation, and atherosclerosis. International Journal ofObesity.2003,27, S35–S40.
3. Faure E, Equils O, Sieling PA, et al. Bacterial lipopolysaccharide activates NF-kappaB throughtoll-like receptor4(TLR-4) in cultured human dermal endothelial cells. Differential expression ofTLR-4and TLR-2in endothelial cells.J Biol Chem.2000Apr14;275(15):11058-63.
4.周云,沃兴德,卢德赵. RAW264．7巨噬细胞源性泡沫细胞模型的建立及鉴定.中国动脉硬化杂志.2010,18(9),687-690.
5. Adorni MP, Zimetti F, Puntoni M, et al. Cellular cholesterol efflux and cholesterol loading capacityof serum: effects of LDL-apheresis. J Lipid Res.2012Mar12.[Epub ahead of print]
6. Orsoni A, Villard EF, Bruckert E, et al. Robillard P,Impact of LDL apheresis on atheroprotectivereverse cholesterol transport pathway in familial hypercholesterolemia. J Lipid Res.2012;53(4):767-75.
7. Ohashi R, Mu H, Wang X, et al. Reverse cholesterol transport and cholesterol efflux inatherosclerosis. QJM.2005Dec;98(12):845-56.
8. Cascieri MA.The potential for novel anti-inflammatory therapies for coronary artery disease.NatRev Drug Discov.2002;1(2):122-30.
9. Kwok SK, Cho ML, Her YM, et al. TLR2ligation induces the production of IL-23/IL-17via IL-6,STAT3and NF-kB pathway in patients with primary Sjogren's syndrome. Arthritis Res Ther.2012Mar14;14(2):R64.[Epub ahead of print]
10.严杰,方平楚.幽门螺杆菌脂多糖化学组成和SDS-PAGE特性的研究.中国人兽共患病杂志.1996;12(3):19-21
11. Ahmadzadeh E, Zarkesh-Esfahani H, Roghanian R, et al. Comparison of Helicobacter pylori andEscherichia coli in induction of TNF-alpha mRNA from human peripheral blood mononuclear cells.Indian J Med Microbiol.2010;28(3):233-7.
12. Endemann G, Stanton LW, Madden KS, et al. CD36is a receptor for oxidized low densitylipoprotein.J Biol Chem.1993;268(16):11811-6.
1. Lien, Egil PhD; Ingalls, Robin R. MD.Toll-like receptors. Critical Care Medicine:2005,33(12)-ppS457-S459
2.朱文敏,吴士尧. Toll样受体与心血管疾病.国际心血管病杂志,2008,35(6):377-379
3. Gasbarrini G, Racco S, Franceschi F, et al. Helicobacter pylori infection: from gastric to systemicdisease. Recenti Prog Med.2010Jan;101(1):27-33.
4.严杰,方平楚.幽门螺杆菌脂多糖化学组成和SDS-PAGE特性的研究.中国人兽共患病杂志.1996;12(3):19-21
5. Ahmadzadeh E, Zarkesh-Esfahani H, Roghanian R, et al. Comparison of Helicobacter pylori andEscherichia coli in induction of TNF-alpha mRNA from human peripheral blood mononuclear cells.Indian J Med Microbiol.2010;28(3):233-7.
6. Endemann G, Stanton LW, Madden KS, et al. CD36is a receptor for oxidized low densitylipoprotein.J Biol Chem.1993;268(16):11811-6.
7. Smith SM, Moran AP, Duggan SP,, et al. Tribbles3: a novel regulator of TLR2-mediated signalingin response to Helicobacter pylori lipopolysaccharide. J Immunol.2011;186(4):2462-71.
8. Teupser D, Kretzschmar D, Tennert C, et al. Effect of macrophage overexpression of murine liverX receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice. ArteriosclerThromb Vasc Biol.2008;28(11):2009-15.
1、Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med.1999;340:115–126.
2、G ran K. Hansson. Inflammation, Atherosclerosis, and Coronary Artery Disease. NEngl J Med.2005;352:1685-95.
3、Gasbarrini G, Racco S, Franceschi F, et al. Helicobacter pylori infection: fromgastric to systemic disease. Recenti Prog Med.2010Jan;101(1):27-33.
4、Prelipcean CC, Mihai C, Gog lniceanu P, et al. Extragastric manifestations ofHelicobacter pylori infection.Rev Med Chir Soc Med Nat Iasi.2007Jul-Sep;111(3):575-83.
5、Franceschi F, Gasbarrini A.Helicobacter pylori and extragastric diseases.Best PractRes Clin Gastroenterol.2007;21(2):325-34.
6、Farsak B, Yildirir A, Aky n Y, et al. Detection of Chlamydia pneumoniae andHelicobacter pylori DNA in Human Atherosclerotic Plaques by PCR. J Clin Microbiol.2000Dec;38(12):4408-11.
7、Kaplan M, Yavuz SS, Cinar B, et al. Detection of Chlamydia pneumoniae andHelicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chainreaction. Int J Infect Dis.2006Mar;10(2):116-23.
8、Kowalski M, Pawlik M, Konturek JW, et al. Helicobacter pylori infection incoronary artery disease. J Physiol Pharmacol.2006Sep;57Suppl3:101-11.
9、Elkind MS, Luna JM, Moon YP, et al. Infectious burden and carotid plaquethickness: the northern Manhattan study. Stroke.2010Mar;41(3):e117-22.10、 Sawayama Y, Ariyama I, Hamada M, et al. Association between chronicHelicobacter pylori infection and acute ischemic stroke: Fukuoka HarasanshinAtherosclerosis Trial (FHAT). Atherosclerosis.2005；178（2）：303-9.
11、Cremonini F, Gabrielli M, Gasbarrini G, et al. The relationship between chronic H.pylori infection, CagA seropositivity and stroke: meta-analysis. Atherosclerosis.2004；173,（2）：253-9.
12、Grau AJ, Buggle F, Lichy C, et al. Helicobacter pylori infection as an independentrisk factor for cerebral ischemia of atherothrombotic origin. J Neurol Sci.2001May1;186(1-2):1-5.
13、崔梅花,胡伏莲.幽门螺杆菌的致病因子.世界华人消化杂志.2003;11(12):1993-6.
14、Han XP, Wang P, Li JK, et al. Advances in research on Helicobacter pylorivirulence factors. Shijie Huaren Xiaohua Zazhi2009;17(22):2292-7.
15、Lemke LB, Ge Z, Whary MT, et al. Concurrent Helicobacterbilis infection inC57BL/6mice attenuates proinflammatory H. pylori-induced gastricpathology. InfectImmun.2009;77:2147-2158.
16、Koyama S. Apoptotic depletion of infiltrating mucosal lymphocytes associatedwith Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium:human glandular stomach as a site of immune privilege. Dig Dis Sci.2000Apr;45(4):773-80.
17、Ro ankovi PB, Huzjan AL, Cupi H, et al. Influence of CagA-positiveHelicobacter pylori strains on atherosclerotic carotid disease. J Neurol.2011May;258(5):753-61.
18、Leunk RD, Johnson PT, David BC, et al. Cytotoxic activity in broth-culturefiltrates of Campylobacter pylori. J Med Microbiol1988;26:93-99.
19、Tobin NP, Henehan GT, Murphy RP, et al. Helicobacter pylori-induced inhibitionof vascular endothelial cell functions: a role for VacA-dependent nitric oxide reduction.Am J Physiol Heart Circ Physiol.2008Oct;295(4):H1403-13. Epub2008Jul25.
20、Bettina Gebert, Wolfgang Fischer, Evelyn Weiss, et al. Helicobacter pyloriVacuolating Cytotoxin Inhibits T Lymphocyte Activation. Science22August2003: Vol.301no.5636pp.1099-1102.
21、Manuel R. Amieva, Emad M. El–Omar. Host-Bacterial Interactions in Helicobacterpylori Infection. Gastroenterology.2008；134：306-323.
22、Dunn BE,Cohen H,Blaser MJ.Helicobacter pylori. Clinl Microbiol Rev,1997;10:720-741.
23、Lee A, Fox J, Hazell S, et al. Pathogenicity of Helicobacter pylori: a perspective.Infect Immun,1993;61:1601-1610.
24、Harris PR, Mobley HL, Perez-Perez GI, et al. Helicobacter pylori urease is a potentstimulus of mononuclear phagocyte activation and inflammatory cytokine production.Gastroenterology.1996Aug;111(2):419-25.
25、Cover TL, Puryear W, Perez-Perez GI, et al. Effect of urease on HeLa cellvacuolation induced by Helicobacter pylori cytotoxin. Infect Immun.1991Apr;59(4):1264-70.
26、Evans DJ Jr, Evans DG, Lampert HC, et al. Identification of four new prokaryoticbacterioferritins, from Helicobacter pylori, Anabaena variabilis, Bacillus subtilis andTreponema pallidum, by analysis of gene sequences. Gene.1995Feb3;153(1):123-7.
27、Montecucco C, de Bernard M. Molecular and cellular mechanisms of action of thevacuolating cytotoxin (VacA) and neutrophil-activating protein (HP-NAP) virulencefactors of Helicobacter pylori. Microbes and Infection.Volume5, Issue8, July2003, Pages715-721.
28、Fan XG，Liu ZB. Immunopathogenesis of Helicobacter pylori infection. HuarenXiaohua Zazhi,1998;6(2):155-157.
29、Polenghi A, Bossi F, Fischetti F, et al. The neutrophil-activating protein ofHelicobacter pylori crosses endothelia to promote neutrophil adhesion in vivo. J Immunol.2007Feb1;178(3):1312-20.
30、Engstrand L, Scheynius A, P hlson C, et al. An increased number of gamma/deltaT-cells and gastric epithelial cell expression of the groEL stress-protein homologue inHelicobacter pylori-associated chronic gastritis of the antrum. Am J Gastroenterol.1991Aug;86(8):976-80.
31、Dubreuil JD, Giudice GD, Rappuoli R. Helicobacter pylori Interactions with HostSerum and Extracellular Matrix Proteins: Potential Role in the Infectious Process.Microbiol Mol Biol Rev.2002Dec;66(4):617-29.
32、Lenzi C, Palazzuoli A, Giordano N, et al. H pylori infection and systemicantibodies to CagA and heat shock protein60in patients with coronary heart disease.World J Gastroenterol.2006Dec28;12(48):7815-20.
33、Ayada K, Yokota K, Kobayashi K, et al. Chronic infections and atherosclerosis.Clin Rev Allergy Immunol.2009Aug;37(1):44-8.
34、Ayada K, Yokota K, Kobayashi K, et al. Chronic infections and atherosclerosis.Ann N Y Acad Sci.2007Jun;1108:594-602.
35、Slomiany BL, Piotrowski J, Slomiany A. Effect of sucralfate on gastric mucosalinflammatory responses induced by Helicobacter pylori lipopolysaccharide. Scand JGastroenterol.1998Sep;33(9):916-22.
36、 Innocenti M, Svennerholm AM, Quiding-J rbrink M. Helicobacter pylorilipopolysaccharides preferentially induce CXC chemokine production in human monocytes.Infect Immun.2001Jun;69(6):3800-8.
37、 Kawahara T, Teshima S, Oka A,et al. Type I Helicobacter pylorilipopolysaccharide stimulates toll-like receptor4and activates mitogen oxidase1in gastricpit cells. Infect Immun.2001Jul;69(7):4382-9.
38、Grebowska A, Rechciński T, Bak-Romaniszyn L,et al. Potential role of LPS in theoutcome of Helicobacter pylori related diseases. Pol J Microbiol.2006;55(1):25-30.39.Whittle BJ, Morschl E, Pozsár J,et al. Helicobacter pylori lipopolysaccharideprovokes iNOS-mediated acute systemic microvascular inflammatory responses in ratcardiac, hepatic, renal and pulmonary tissues. J Physiol Paris.2001Jan-Dec;95(1-6):257-9.
40、Libby P, Ridker P M, Maseri A, et al. Inflammation and Atherosclerosis.Circulation.2002;105:1135.
41、Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independentpredictor of the rate of increase in early carotid atherosclerosis. Circulation.2001Jul3;104(1):63-7.
42、Ridker PM, Danielson E, Fonseca FA,et al. Rosuvastatin to prevent vascular eventsin men and women with elevated C-reactive protein. N Engl J Med.2008Nov20;359(21):2195-207.
43、Corrado E, Rizzo M, Tantillo R.,et al. Markers of inflammation and infectioninfluence the outcome of patients with baseline asymptomatic carotid lesions: a5-yearfollow-up study. Stroke.2006Feb;37(2):482-6. Epub2005Dec22.
44、Jafarzadeh A, Hassanshahi GH, Nemati M, et al. Serum levels of high-sensitivityC-reactive protein (hs-CRP)in Helicobacter pylori-infected peptic ulcer patients and itsassociation with bacterial CagA virulence factor.Dig Dis Sci.2009Dec;54(12):2612-6.
45、El-Mashad N, El-Emshaty WM, Arfat MS,et al. Relation of Cag-A-positiveHelicobacter pylori strain and some inflammatory markers in patients with ischemic heartdiseases. Egypt J Immunol.2009;16(1):39-47.
46、Kebapcilar L, Bilgir O, Cetinkaya E, et al. The effect of Helicobacter pylorieradication on macrophage migration inhibitory factor, C-reactive protein and fetuin-alevels. Clinics (Sao Paulo).2010Jun;65(8):799-802.
47、Xiao Q, Mandal K, Schett G, et al. Association of Serum-Soluble Heat ShockProtein60With Carotid Atherosclerosis. Stroke.2005;36:2571.
48、Zhu J, Quyyumi AA, Rott D, et al. Antibodies to Human Heat-Shock Protein60Are Associated With the Presence and Severity of Coronary Artery Disease. Circulation.2001;103:1071.
49、Lenzi C, Palazzuoli A, Giordano N. H. pylori infection and systemic antibodies toCagA and heat shock protein60in patients with coronary heart disease. World JGastroenterol.2006Dec28;12(48):7815-20.
50、AndriéR, Braun P, Heinrich KW. Prevalence of intimal pathogen burden in acutecoronary syndromes. Z Kardiol.2003Aug;92(8):641-9.
51、王广,王育珊,陈星海.幽门螺杆菌HSP60与急性冠脉综合征及病变程度关系的研究.中国实验诊断学.2009,13(10):1397-8.
52、Okada T, Ayada K, Usui S, et al. Antibodies against heat shock protein60derivedfrom Helicobacter pylori: diagnostic implications in cardiovascular disease. J Autoimmun.2007Sep-Nov;29(2-3):106-15.
53、 Watanabe N, Ikeda U. Matrix metalloproteinases and atherosclerosis. CurrAtheroscler Rep.2004Mar;6(2):112-20.
54、Beaudeux JL, Giral P, Bruckert E. Matrix metalloproteinases, inflammation andatherosclerosis: therapeutic perspectives. Clin Chem Lab Med.2004Feb;42(2):121-31.
55、刘龙斌,郭航远,池菊芳.基质金属蛋白酶在动脉粥样硬化中的研究进展.中国全科医学,2009，12(7A):1232-4.
56、W gs ter D, Zhu C, Bj rkegren J, et al. MMP-2and MMP-9are prominent matrixmetalloproteinases during atherosclerosis development in the Ldlr-/-Apob100/100mouse.Int J Mol Med.2011Aug;28(2):247-53.
57、Mori N. Helicobacter pylori induces matrix metalloproteinase expression. NipponRinsho.2005Nov;63Suppl11:138-45.
58、Kundu P, Mukhopadhyay AK, Patra R, et al. Cag pathogenicity island-independentup-regulation of matrix metalloproteinases-9and-2secretion and expression in mice byHelicobacter pylori infection. J Biol Chem.2006Nov10;281(45):34651-62.
59、Rautelin HI, Oksanen AM, Veijola LI, Sipponen PI, Tervahartiala TI, Sorsa TA,Lauhio A.Enhanced systemic matrix metalloproteinase response in Helicobacter pylorigastritis.Ann Med.2009;41(3):208-15.
60、Kountouras J, Zavos C, Deretzi G, et al. Helicobacter pylori may be involved instroke pathophysiology by altering tumor necrosis factor-α and matrix metalloproteinases.Eur J Neurol.2011Jul;18(7).
61、Neta R, Sayers TJ, Oppenheim JJ. Relationship of TNF to interleukins. ImmunolSer.1992;56:499-566.
62、Sbarsi I, Falcone C, Boiocchi C, et al. Inflammation and atherosclerosis: the role ofTNF and TNF receptors polymorphisms in coronary artery disease. Int J ImmunopatholPharmacol.2007Jan-Mar;20(1):145-54.
63、Haddy N, Sass C, Droesch S, et al. IL-6, TNF-alpha and atherosclerosis riskindicators in a healthy family population: the STANISLAS cohort. Atherosclerosis.2003Oct;170(2):277-83.
64、Elkind MS, Cheng JF, Boden-Albala B. Tumor Necrosis Factor Receptor LevelsAre Associated With Carotid Atherosclerosis. Stroke.2002;33:31.
65、Elkind MS, Cheng J, Boden-Albala B, et al. Elevated white blood cell count andcarotid plaque thickness: the northern Manhattan stroke study. Stroke，2001，32:842.
66、Tufano MA，rossano f，catalanotti p，et al． Immunobiological Activitives ofHelicobacter Pylor Porins． Infect Immun.1994；62：1392.
67、Laurila A, Bloigu A, N yh S，et al． Chronic Chlamydia pneumoniae infection isassociated with a serum lipid profile known to be a risk factor for atherosclerosis.Arterioscler Thromb Vasc Biol.1997Nov;17(11):2910-3.
68、Adiloglu AK, Can R, Nazli C，et al． Ectasia and severe atherosclerosis:relationships with chlamydia pneumoniae, helicobacterpylori, and inflammatory markers.Tex Heart Inst J.2005;32(1):21-7.
69、Hamed SA, Amine NF, Galal GM，et al． Vascular risks and complications indiabetes mellitus: the role of helicobacter pylori infection. J Stroke Cerebrovasc Dis.2008Mar-Apr;17(2):86-94.
70、Cybulsky MI,Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyteadhesion molecule during atherogenesis. Science,1991,251(4995):788791.
71、 O'Brien KD, McDonald TO, Chait A, et al. Neovascular expression ofEselectin,intercellular adhesion molecule1in human atherosclerosis and their relation tointimal leukocyte content. Circulation,1996,93(4):672-82.
72、Hwang SJ; Ballantyne CM, Sharrett AR, et al. Circulating Adhesion MoleculesVCAM-1, ICAM-1, and E-selectin in Carotid Atherosclerosis and Incident Coronary HeartDisease Cases. Circulation.1997;96:4219-25.
73、Ameriso SF, Fridman EA, Leiguarda RC, et al. Detection of Helicobacter pylori inhuman carotid atherosclerotic plaques. Stroke.2001Feb;32(2):385-91.
74、Yoshida N, Kassai K, Murase H, et al. Effects of Helicobacter pylori water extracton expression of endothelial adhesion molecules. Can J Gastroenterol.2004Jun;18(6):387-91.
75、Oshima T, Ozono R, Yano Y, et al. Association of Helicobacter pylori infectionwith systemic inflammation and endothelial dysfunction in healthy male subjects. J AmColl Cardiol.2005Apr19;45(8):1219-22.
76、Schumacher A, Seljeflot I, Lerker d AB, et al. Does infection with Chlamydiapneumoniae and/or Helicobacter pylori increase the expression of endothelial cell adhesionmolecules in humans? Clin Microbiol Infect.2002Oct;8(10):654-61.
77、Liuba P, Pesonen E, Paakkari I, et al. Co-infection with Chlamydia pneumoniaeand Helicobacter pylori results in vascular endothelial dysfunction and enhanced VCAM-1expression in apoE-knockout mice. J Vasc Res.2003Mar-Apr;40(2):115-22.
78、Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis ofischemic stroke: a systematic review. Stroke.2008Oct;39(10):2902-9. Epub2008Jul24.
79、Cojocaru IM, Cojocaru M, Iliescu I, et al. Plasma myeloperoxidase levels inpatients with acute ischemic stroke. Rom J Intern Med.2010;48(1):101-4.
80、Wang CA, Liu YC, Du SY, et al. Helicobacter pylori neutrophil-activating proteinpromotes myeloperoxidase release from human neutrophils. Biochem Biophys ResCommun.2008Dec5;377(1):52-6.
81、Nazligul Y, Aslan M, Horoz M, et al. The effect on serum myeloperoxidase activityand oxidative status of eradication treatment in patients Helicobacter pylori infected. ClinBiochem.2011Jun;44(8-9):647-9.
82、Durrington PN, Mackness B, Mackness MI, et al. Paraoxonase and Atherosclerosis.Arteriosclerosis, Thrombosis, and Vascular Biology.2001;21:473-80.83、 Schmidt H, Schmidt R, Niederkorn K. Paraoxonase PON1PolymorphismLeu-Met54Is Associated With Carotid Atherosclerosis. Stroke.1998;29:2043-48.
84、Ranade K, Kirchgessner TG, Iakoubova OA, et al. Evaluation of the paraoxonasesas candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase1gene isassociated with increased risk of stroke. Stroke.2005Nov;36(11):2346-50.85、 Aslan M, Nazligul Y, Horoz M, et al. Serum paraoxonase-1activity inHelicobacter pylori infected subjects. Atherosclerosis.2008Jan;196(1):270-4.
86、Akbas HS, Basyigit S, Suleymanlar I, et al. The assessment of carotid intimamedia thickness and serum paraoxonase-1activity in Helicobacter pylori positive subjects.Lipids Health Dis.2010Aug30;9:92.
87、Páramo JA, Rodríguez JA, Orbe J, et al. Fibrinogen. An old hemostatic proteinwith a new function: non-invasive marker of subclinical atherosclerosis. Med Clin (Barc).2005May28;124(20):790-4.
88、Nazmi A, Diez-Roux AV, Jenny NS, et al. The influence of persistent pathogens oncirculating levels of inflammatory markers: a cross-sectional analysis from theMulti-Ethnic Study of Atherosclerosis. BMC Public Health.2010Nov17;10:706.
89、Pellicano R, Oliaro E, Fagoonee S, et al. Clinical and biochemical parametersrelated to cardiovascular disease after Helicobacter pylori eradication. Int Angiol.2009Dec;28(6):469-73.
90、Longo-Mbenza B, Nkondi Nsenga J, Vangu Ngoma D. Prevention of the metabolicsyndrome insulin resistance and the atherosclerotic diseases in Africans infected byHelicobacter pylori infection and treated by antibiotics. Int J Cardiol.2007Oct18;121(3):229-38.
91、B ger RH, Bode-B ger SM, Szuba A. Asymmetric dimethylarginine (ADMA): anovel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation.1998Nov3;98(18):1842-7.
92、Sibal L, Agarwal SC, Home PD, et al. The Role of Asymmetric Dimethylarginine(ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev.2010May;6(2):82-90.
93、Zhang Z, Zou YY, Li FJ, et al. Asymmetric dimethylarginine: A novel biomarker ofgastric mucosal injury? World J Gastroenterol.2011May7;17(17):2178-80.
94、F ndriks L, von Bothmer C, Johansson B, et al. Water extract of Helicobacterpylori inhibits duodenal mucosal alkaline secretion in anesthetized rats. Gastroenterology.1997Nov;113(5):1570-5.
95、Henriksn s J, Atuma C, Phillipson M, et al. Acute effects of Helicobacter pyloriextracts on gastric mucosal blood flow in the mouse. World J Gastroenterol.2009Jan14;15(2):219-25.
96、Marra M, Bonfigli AR, Bonazzi P, et al. Helicobacter. Asymptomatic Helicobacterpylori infection increases asymmetric dimethylarginine levels in healthy subjects.2005Dec;10(6):609-14.
97、Aydemir S, Eren H, Tekin IO, et al. Helicobacter pylori eradication lowers serumasymmetric dimethylarginine levels. Mediators Inflamm.2010;2010:685903.
98、Laurila A, Bloigu A, N yh S, et al. Association of Helicobacter pylori infectionwith elevated serum lipids. Atherosclerosis.1999Jan;142(1):207-10.
99、Satoh H, Saijo Y, Yoshioka E, et al. Helicobacter Pylori infection is a significantrisk for modified lipid profile in Japanese male subjects. J Atheroscler Thromb.2010Oct27;17(10):1041-8.
100、Matsui T. Helicobacter pylori and Arteriosclerosis. Gan To Kagaku Ryoho.2011Mar;38(3):365-9.
101、Corrado E, Novo S. H. Role of inflammation and infection in vascular disease.Acta Chir Belg.2005;105(6):567-79.
102、Polyzos SA, Kountouras J, Zavos C, et al. The association between Helicobacterpylori infection and insulin resistance: a systematic review. Helicobacter.2011Apr;16(2):79-88.
103、Manolakis AC, Tiaka EK, Kapsoritakis AN, et al. Increased fetuin A levels inHelicobacter pylori infection: a missing link between H. pylori and insulin resistance?Diabetologia.2011Feb;54(2):472-4.
2. Brott TG, Hobson RW, Howard G, et al, for the CREST Investigator. Stenting versusEndarterectomy for Treatment of Carotid-Artery Stenosis. N Engl J Med.2010;363:11-23.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med.1999;340:115–126.
4. G ran K. Hansson. Inflammation, Atherosclerosis, and Coronary Artery Disease. NEngl J Med.2005;352:1685-95.
5. AndriéRP, Bauriedel G, Tuleta I, et al. Impact of intimal pathogen burden in acutecoronary syndromes--correlation with inflammation, thrombosis, and autoimmunity.Cardiovasc Pathol.2010;19(6):e205-10.
6. Farsak B, Yildirir A, Aky n Y, et al. Detection of Chlamydia pneumoniae andHelicobacter pylori DNA in Human Atherosclerotic Plaques by PCR. J Clin Microbiol.2000;38(12):4408-11.
7. Kaplan M, Yavuz SS, Cinar B, et al. Detection of Chlamydia pneumoniae andHelicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chainreaction. Int J Infect Dis.2006;10(2):116-23.
8. Kowalski M, Pawlik M, Konturek JW, et al. Helicobacter pylori infection in coronaryartery disease. J Physiol Pharmacol.2006;57Suppl3:101-11.
9. Elkind MS, Luna JM, Moon YP, et al. Infectious burden and carotid plaque thickness:the northern Manhattan study. Stroke.2010;41(3):e117-22.
10. Sawayama Y, Ariyama I, Hamada M, et al. Association between chronic Helicobacterpylori infection and acute ischemic stroke: Fukuoka Harasanshin Atherosclerosis Trial(FHAT). Atherosclerosis.2005;178(2):303-9.
11. Cremonini F, Gabrielli M, Gasbarrini G, et al. The relationship between chronic H.pylori infection, CagA seropositivity and stroke: meta-analysis. Atherosclerosis.2004;173,(2)：253-9.
12.耿学川,赵晓红,韩立荣.脑梗死患者幽门螺杆菌感染状况及其与血脂代谢的关系.神经损伤与功能重建.2010;1:24-6.
13.杨旭,耿学川,李继来,等.缺血性脑卒中患者幽门螺杆菌感染与超敏C反应蛋白相关性研究.中国神经免疫学和神经病学杂志.2010;1:46-8,51.
14.吕淼.幽门螺杆菌与动脉粥样硬化炎症因子相关性分析.现代医药卫生.2009;25(7):1029-30.
15.陶珍.幽门螺杆菌细胞毒素相关蛋白A阳性菌株感染与颈动脉粥样硬化形成的相关性及可能机制研究.第二军医大学博士学位论文.2009（.导师：丁素菊,曲乐丰）
16.陶珍,曲乐丰*,丁素菊,等.颈动脉粥样硬化斑块内幽门螺杆菌-细胞毒素相关蛋白A-IgG抗体的表达与颈动脉粥样硬化性脑梗死的关系.上海医学杂志.2009,32(4):296-8（*通讯作者）
17.陶珍,曲乐丰*,丁素菊,等.幽门螺杆菌感染致兔颈动脉粥样硬化模型的建立.第二军医大学学报,2010,31(1):37-41（*通讯作者）
18.贾庆帅,曲乐丰*,赵宝珍,陶珍.幽门螺杆菌感染致兔颈动脉粥样硬化模型的超声表现.上海医学,2010,33(8):757-60（*通讯作者）
1.中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010.中华神经科杂志.2010;43(2):146-153.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med.1999;340:115–126.
3. Grau AJ, Buggle F, Lichy C, et al. Helicobacter pylori infection as an independent risk factor forcerebral ischemia of atherothrombotic origin. J Neurol Sci.2001;186(1-2):1-5.
4. Mat hiesen EB，Bonaa KH，Joakimsen O．Echolucent plaques are associated with high risk ofischemic cerebrovascular events in carotid stenosis．Circulation.2001;103(17)：21-27.
5.吴莉娟.高频彩超对颈动脉粥样硬化的诊断价值.海南医学.2003;14,8.
6. Prelipcean CC, Mihai C, Gog lniceanu P, et al. Extragastric manifestations of Helicobacter pyloriinfection.Rev Med Chir Soc Med Nat Iasi.2007;111(3):575-583.
7. Franceschi F, Gasbarrini A.Helicobacter pylori and extragastric diseases. Best Pract Res ClinGastroenterol.2007;21(2):325-334.
8. Farsak B, Yildirir A, Aky n Y, et al. Detection of Chlamydia pneumoniae and Helicobacter pyloriDNA in Human Atherosclerotic Plaques by PCR. J Clin Microbiol.2000;38(12):4408-4411.
9. Elkind MS, Luna JM, Moon YP, et al. Infectious burden and carotid plaque thickness: the northernManhattan study. Stroke.2010;41(3):e117-122.
10. Sawayama Y, Ariyama I, Hamada M, et al. Association between chronic Helicobacter pyloriinfection and acute ischemic stroke: Fukuoka Harasanshin Atherosclerosis Trial (FHAT).Atherosclerosis.2005;178(2):303-309.
11. Cremonini F, Gabrielli M, Gasbarrini G, et al. The relationship between chronic H. pylori infection,CagA seropositivity and stroke: meta-analysis. Atherosclerosis.2004;173,(2):253-259.
12. Grau AJ, Buggle F, Lichy C, et al. Helicobacter pylori infection as an independent risk factor forcerebral ischemia of atherothrombotic origin. J Neurol Sci.2001;186(1-2):1-5.
13. Michiel L,Arno W, Peter J, et al. Common Carotid Intima-Media Thickness and Risk of Stroke andMyocardial Infarction-The Rotterdam Study.Circulation.1997;96:1432-1437.
14. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotidintima-media thickness: a systematic review and meta-analysis.Circulation.2007;115(4):459-467.
15. Mookadam F, Tanasunont W, Jalal U, Mookadam M, Wilansky S. Carotid intima-media thicknessand cardiovascular risk.Future Cardiol.2011;7(2):173-182.
16. Akbas HS, Basyigit S, Suleymanlar I, et al.The assessment of carotid intima media thickness andserum paraoxonase-1activity in Helicobacter pylori positive subjects. Lipids Health Dis.2010;9:92.
17.中国医师协会超声医师分会.血管超声检查指南.中华超声影像学杂志.2009;10:911-920.
18. Pasceri V, Patti G, Cammarota G, et al. Virulent strains of Helicobacter pylori and vascular diseases:a meta-analysis. Am Heart J.2006;151:1215–1222.
19. Sebastián F, Esteban A, Ramón C, et al. Detection of Helicobacter pylori in Human CarotidAtherosclerotic Plaques. Stroke.2001;32:385-391.
20. Ro ankovi PB, Huzjan AL, Cupi H, et al. Influence of CagA-positive Helicobacter pylori strainson atherosclerotic carotid disease.J Neurol.2011;258(5):753-761.
21. Cremonini F, Gabrielli M, Gasbarrini G, et al. The relationship between chronic H. pylori infection,CagA seropositivity and stroke: meta-analysis. Atherosclerosis.2004;173,(2):253-259.
22. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med.1999;340:115–126.
23. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarkerdiscovery and risk prediction.Clin Chem.2008;54(1):24-38.
24. Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: asystematic review. Stroke.2008;39(10):2902-2909.
25. Cojocaru IM, Cojocaru M, Iliescu I, et al. Plasma myeloperoxidase levels in patients with acuteischemic stroke. Rom J Intern Med.2010;48(1):101-104.
26. Wang CA, Liu YC, Du SY, et al. Helicobacter pylori neutrophil-activating protein promotesmyeloperoxidase release from human neutrophils. Biochem Biophys Res Commun.2008;377(1):52-56.
27. Nazligul Y, Aslan M, Horoz M, et al. The effect on serum myeloperoxidase activity and oxidativestatus of eradication treatment in patients Helicobacter pylori infected. Clin Biochem.2011;44(8-9):647-649.
28. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep.2004;6(2):112-120.
29. Mori N. Helicobacter pylori induces matrix metalloproteinase expression. Nippon Rinsho.2005;63Suppl11:138-145.
30. Kundu P, Mukhopadhyay AK, Patra R, et al. Cag pathogenicity island-independent up-regulationof matrix metalloproteinases-9and-2secretion and expression in mice by Helicobacter pyloriinfection. J Biol Chem.2006;281(45):34651-34662.
31. Rautelin HI, Oksanen AM, Veijola LI, Sipponen PI, Tervahartiala TI, Sorsa TA, LauhioA.Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis. Ann Med.2009;41(3):208-215.
32. Kountouras J, Zavos C, Deretzi G, et al. Helicobacter pylori may be involved in strokepathophysiology by altering tumor necrosis factor-α and matrix metalloproteinases. Eur J Neurol.2011;18(7).
33. Vittos O, Toana B, Vittos A, et al. Lipoprotein-associated phospholipase A2(Lp-PLA2): a reviewof its role and significance as a cardiovascular biomarker. Biomarkers.2012Mar9[Epub ahead ofprint].
34. Serruys PW，Heictor M，Garcia HM，et a1． Effects of the directlipoprotein-associatedphospholipase A2inhibitor darapladib onhuman coronary atherosclerotic plaque． Circulation，2008;118:1171-1182．
35. Libby P, Ridker P M, Maseri A, et al. Inflammation and Atherosclerosis. Circulation.2002;105:1135
36. Corrado E, Rizzo M, Tantillo R.,et al. Markers of inflammation and infection influence theoutcome of patients with baseline asymptomatic carotid lesions: a5-year follow-up study. Stroke.2006;37(2):482-486.
37. Jafarzadeh A, Hassanshahi GH, Nemati M, et al. Serum levels of high-sensitivity C-reactiveprotein (hs-CRP)in Helicobacter pylori-infected peptic ulcer patients and its association withbacterial CagA virulence factor.Dig Dis Sci.2009;54(12):2612-2616.
38. El-Mashad N, El-Emshaty WM, Arfat MS,et al. Relation of Cag-A-positive Helicobacter pyloristrain and some inflammatory markers in patients with ischemic heart diseases. Egypt J Immunol.2009;16(1):39-47.
39. Kebapcilar L, Bilgir O, Cetinkaya E, et al. The effect of Helicobacter pylori eradication onmacrophage migration inhibitory factor, C-reactive protein and fetuin-a levels. Clinics (Sao Paulo).2010;65(8):799-802.
1. Farsak B, Yildirir A, Aky n Y, et al. Detection of Chlamydia pneumoniae and Helicobacter pyloriDNA in Human Atherosclerotic Plaques by PCR. J Clin Microbiol.2000Dec;38(12):4408-11.
2. Kaplan M, Yavuz SS, Cinar B, et al. Detection of Chlamydia pneumoniae and Helicobacter pyloriin atherosclerotic plaques of carotid artery by polymerase chain reaction. Int J Infect Dis.2006Mar;10(2):116-23.
3. Casscells W, Naghavi M, Willerson JT. Vulnerable Atherosclerotic Plaque：A Multifocal Disease.Circulation.2003;107:2072-75
4. Innocenti M, Svennerholm AM, Quiding-J rbrink M. Helicobacter pylori lipopolysaccharidespreferentially induce CXC chemokine production in human monocytes. Infect Immun.2001Jun;69(6):3800-8.
5. M. Madjid, M. Ali, J.T. Willerson. Lipoprotein-associated phospholipase A2as a novel risk markerfor cardiovascular disease: a systematic review of the literature. Tex Heart Inst J,37(2010), pp.25–39
6. Z. Mallat, G. Lambeau, A. Tedgui. Lipoprotein-associated and secreted phospholipases A2incardiovascular disease: roles as biological effectors and biomarkers. Circulation,122(2010), pp.2183–2200
7. M.H. Davidson, M.A. Corson, M.J. Alberts, et al. Consensus panel recommendation forincorporating lipoprotein-associated phospholipase A2testing into cardiovascular disease riskassessment guidelines. Am J Cardiol,101(2008), pp.51F–57F
8. Hazen SL, Heinecke JW.3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzedoxidation, is markedly elevated in low density lipoprotein isolated from human atheroscleroticintima. J Clin Invest.1997;99:2075–2081.
9. Watanabe N, Ikeda U. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep.2004Mar;6(2):112-20.
10. Beaudeux JL, Giral P, Bruckert E. Matrix metalloproteinases, inflammation and atherosclerosis:therapeutic perspectives. Clin Chem Lab Med.2004Feb;42(2):121-31.
11.刘龙斌,郭航远,池菊芳.基质金属蛋白酶在动脉粥样硬化中的研究进展.中国全科医学,2009，12(7A):1232-4.
12. W gs ter D, Zhu C, Bj rkegren J, et al. MMP-2and MMP-9are prominent matrixmetalloproteinases during atherosclerosis development in the Ldlr-/-Apob100/100mouse. Int JMol Med.2011Aug;28(2):247-53.
13. Mori N. Helicobacter pylori induces matrix metalloproteinase expression. Nippon Rinsho.2005Nov;63Suppl11:138-45.
14. Kundu P, Mukhopadhyay AK, Patra R, et al. Cag pathogenicity island-independent up-regulationof matrix metalloproteinases-9and-2secretion and expression in mice by Helicobacter pyloriinfection. J Biol Chem.2006Nov10;281(45):34651-62.
15. Rautelin HI, Oksanen AM, Veijola LI, Sipponen PI, Tervahartiala TI, Sorsa TA, LauhioA.Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.Ann Med.2009;41(3):208-15.
1.易光辉.动脉粥样硬化.中国动脉硬化杂志.2005,1:96-96.
2. MacRae F, Sergio F. Macrophages, inflammation, and atherosclerosis. International Journal ofObesity.2003,27, S35–S40.
3. Faure E, Equils O, Sieling PA, et al. Bacterial lipopolysaccharide activates NF-kappaB throughtoll-like receptor4(TLR-4) in cultured human dermal endothelial cells. Differential expression ofTLR-4and TLR-2in endothelial cells.J Biol Chem.2000Apr14;275(15):11058-63.
4.周云,沃兴德,卢德赵. RAW264．7巨噬细胞源性泡沫细胞模型的建立及鉴定.中国动脉硬化杂志.2010,18(9),687-690.
5. Adorni MP, Zimetti F, Puntoni M, et al. Cellular cholesterol efflux and cholesterol loading capacityof serum: effects of LDL-apheresis. J Lipid Res.2012Mar12.[Epub ahead of print]
6. Orsoni A, Villard EF, Bruckert E, et al. Robillard P,Impact of LDL apheresis on atheroprotectivereverse cholesterol transport pathway in familial hypercholesterolemia. J Lipid Res.2012;53(4):767-75.
7. Ohashi R, Mu H, Wang X, et al. Reverse cholesterol transport and cholesterol efflux inatherosclerosis. QJM.2005Dec;98(12):845-56.
8. Cascieri MA.The potential for novel anti-inflammatory therapies for coronary artery disease.NatRev Drug Discov.2002;1(2):122-30.
9. Kwok SK, Cho ML, Her YM, et al. TLR2ligation induces the production of IL-23/IL-17via IL-6,STAT3and NF-kB pathway in patients with primary Sjogren's syndrome. Arthritis Res Ther.2012Mar14;14(2):R64.[Epub ahead of print]
10.严杰,方平楚.幽门螺杆菌脂多糖化学组成和SDS-PAGE特性的研究.中国人兽共患病杂志.1996;12(3):19-21
11. Ahmadzadeh E, Zarkesh-Esfahani H, Roghanian R, et al. Comparison of Helicobacter pylori andEscherichia coli in induction of TNF-alpha mRNA from human peripheral blood mononuclear cells.Indian J Med Microbiol.2010;28(3):233-7.
12. Endemann G, Stanton LW, Madden KS, et al. CD36is a receptor for oxidized low densitylipoprotein.J Biol Chem.1993;268(16):11811-6.
1. Lien, Egil PhD; Ingalls, Robin R. MD.Toll-like receptors. Critical Care Medicine:2005,33(12)-ppS457-S459
2.朱文敏,吴士尧. Toll样受体与心血管疾病.国际心血管病杂志,2008,35(6):377-379
3. Gasbarrini G, Racco S, Franceschi F, et al. Helicobacter pylori infection: from gastric to systemicdisease. Recenti Prog Med.2010Jan;101(1):27-33.
4.严杰,方平楚.幽门螺杆菌脂多糖化学组成和SDS-PAGE特性的研究.中国人兽共患病杂志.1996;12(3):19-21
5. Ahmadzadeh E, Zarkesh-Esfahani H, Roghanian R, et al. Comparison of Helicobacter pylori andEscherichia coli in induction of TNF-alpha mRNA from human peripheral blood mononuclear cells.Indian J Med Microbiol.2010;28(3):233-7.
6. Endemann G, Stanton LW, Madden KS, et al. CD36is a receptor for oxidized low densitylipoprotein.J Biol Chem.1993;268(16):11811-6.
7. Smith SM, Moran AP, Duggan SP,, et al. Tribbles3: a novel regulator of TLR2-mediated signalingin response to Helicobacter pylori lipopolysaccharide. J Immunol.2011;186(4):2462-71.
8. Teupser D, Kretzschmar D, Tennert C, et al. Effect of macrophage overexpression of murine liverX receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice. ArteriosclerThromb Vasc Biol.2008;28(11):2009-15.
1、Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med.1999;340:115–126.
2、G ran K. Hansson. Inflammation, Atherosclerosis, and Coronary Artery Disease. NEngl J Med.2005;352:1685-95.
3、Gasbarrini G, Racco S, Franceschi F, et al. Helicobacter pylori infection: fromgastric to systemic disease. Recenti Prog Med.2010Jan;101(1):27-33.
4、Prelipcean CC, Mihai C, Gog lniceanu P, et al. Extragastric manifestations ofHelicobacter pylori infection.Rev Med Chir Soc Med Nat Iasi.2007Jul-Sep;111(3):575-83.
5、Franceschi F, Gasbarrini A.Helicobacter pylori and extragastric diseases.Best PractRes Clin Gastroenterol.2007;21(2):325-34.
6、Farsak B, Yildirir A, Aky n Y, et al. Detection of Chlamydia pneumoniae andHelicobacter pylori DNA in Human Atherosclerotic Plaques by PCR. J Clin Microbiol.2000Dec;38(12):4408-11.
7、Kaplan M, Yavuz SS, Cinar B, et al. Detection of Chlamydia pneumoniae andHelicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chainreaction. Int J Infect Dis.2006Mar;10(2):116-23.
8、Kowalski M, Pawlik M, Konturek JW, et al. Helicobacter pylori infection incoronary artery disease. J Physiol Pharmacol.2006Sep;57Suppl3:101-11.
9、Elkind MS, Luna JM, Moon YP, et al. Infectious burden and carotid plaquethickness: the northern Manhattan study. Stroke.2010Mar;41(3):e117-22.10、 Sawayama Y, Ariyama I, Hamada M, et al. Association between chronicHelicobacter pylori infection and acute ischemic stroke: Fukuoka HarasanshinAtherosclerosis Trial (FHAT). Atherosclerosis.2005；178（2）：303-9.
11、Cremonini F, Gabrielli M, Gasbarrini G, et al. The relationship between chronic H.pylori infection, CagA seropositivity and stroke: meta-analysis. Atherosclerosis.2004；173,（2）：253-9.
12、Grau AJ, Buggle F, Lichy C, et al. Helicobacter pylori infection as an independentrisk factor for cerebral ischemia of atherothrombotic origin. J Neurol Sci.2001May1;186(1-2):1-5.
13、崔梅花,胡伏莲.幽门螺杆菌的致病因子.世界华人消化杂志.2003;11(12):1993-6.
14、Han XP, Wang P, Li JK, et al. Advances in research on Helicobacter pylorivirulence factors. Shijie Huaren Xiaohua Zazhi2009;17(22):2292-7.
15、Lemke LB, Ge Z, Whary MT, et al. Concurrent Helicobacterbilis infection inC57BL/6mice attenuates proinflammatory H. pylori-induced gastricpathology. InfectImmun.2009;77:2147-2158.
16、Koyama S. Apoptotic depletion of infiltrating mucosal lymphocytes associatedwith Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium:human glandular stomach as a site of immune privilege. Dig Dis Sci.2000Apr;45(4):773-80.
17、Ro ankovi PB, Huzjan AL, Cupi H, et al. Influence of CagA-positiveHelicobacter pylori strains on atherosclerotic carotid disease. J Neurol.2011May;258(5):753-61.
18、Leunk RD, Johnson PT, David BC, et al. Cytotoxic activity in broth-culturefiltrates of Campylobacter pylori. J Med Microbiol1988;26:93-99.
19、Tobin NP, Henehan GT, Murphy RP, et al. Helicobacter pylori-induced inhibitionof vascular endothelial cell functions: a role for VacA-dependent nitric oxide reduction.Am J Physiol Heart Circ Physiol.2008Oct;295(4):H1403-13. Epub2008Jul25.
20、Bettina Gebert, Wolfgang Fischer, Evelyn Weiss, et al. Helicobacter pyloriVacuolating Cytotoxin Inhibits T Lymphocyte Activation. Science22August2003: Vol.301no.5636pp.1099-1102.
21、Manuel R. Amieva, Emad M. El–Omar. Host-Bacterial Interactions in Helicobacterpylori Infection. Gastroenterology.2008；134：306-323.
22、Dunn BE,Cohen H,Blaser MJ.Helicobacter pylori. Clinl Microbiol Rev,1997;10:720-741.
23、Lee A, Fox J, Hazell S, et al. Pathogenicity of Helicobacter pylori: a perspective.Infect Immun,1993;61:1601-1610.
24、Harris PR, Mobley HL, Perez-Perez GI, et al. Helicobacter pylori urease is a potentstimulus of mononuclear phagocyte activation and inflammatory cytokine production.Gastroenterology.1996Aug;111(2):419-25.
25、Cover TL, Puryear W, Perez-Perez GI, et al. Effect of urease on HeLa cellvacuolation induced by Helicobacter pylori cytotoxin. Infect Immun.1991Apr;59(4):1264-70.
26、Evans DJ Jr, Evans DG, Lampert HC, et al. Identification of four new prokaryoticbacterioferritins, from Helicobacter pylori, Anabaena variabilis, Bacillus subtilis andTreponema pallidum, by analysis of gene sequences. Gene.1995Feb3;153(1):123-7.
27、Montecucco C, de Bernard M. Molecular and cellular mechanisms of action of thevacuolating cytotoxin (VacA) and neutrophil-activating protein (HP-NAP) virulencefactors of Helicobacter pylori. Microbes and Infection.Volume5, Issue8, July2003, Pages715-721.
28、Fan XG，Liu ZB. Immunopathogenesis of Helicobacter pylori infection. HuarenXiaohua Zazhi,1998;6(2):155-157.
29、Polenghi A, Bossi F, Fischetti F, et al. The neutrophil-activating protein ofHelicobacter pylori crosses endothelia to promote neutrophil adhesion in vivo. J Immunol.2007Feb1;178(3):1312-20.
30、Engstrand L, Scheynius A, P hlson C, et al. An increased number of gamma/deltaT-cells and gastric epithelial cell expression of the groEL stress-protein homologue inHelicobacter pylori-associated chronic gastritis of the antrum. Am J Gastroenterol.1991Aug;86(8):976-80.
31、Dubreuil JD, Giudice GD, Rappuoli R. Helicobacter pylori Interactions with HostSerum and Extracellular Matrix Proteins: Potential Role in the Infectious Process.Microbiol Mol Biol Rev.2002Dec;66(4):617-29.
32、Lenzi C, Palazzuoli A, Giordano N, et al. H pylori infection and systemicantibodies to CagA and heat shock protein60in patients with coronary heart disease.World J Gastroenterol.2006Dec28;12(48):7815-20.
33、Ayada K, Yokota K, Kobayashi K, et al. Chronic infections and atherosclerosis.Clin Rev Allergy Immunol.2009Aug;37(1):44-8.
34、Ayada K, Yokota K, Kobayashi K, et al. Chronic infections and atherosclerosis.Ann N Y Acad Sci.2007Jun;1108:594-602.
35、Slomiany BL, Piotrowski J, Slomiany A. Effect of sucralfate on gastric mucosalinflammatory responses induced by Helicobacter pylori lipopolysaccharide. Scand JGastroenterol.1998Sep;33(9):916-22.
36、 Innocenti M, Svennerholm AM, Quiding-J rbrink M. Helicobacter pylorilipopolysaccharides preferentially induce CXC chemokine production in human monocytes.Infect Immun.2001Jun;69(6):3800-8.
37、 Kawahara T, Teshima S, Oka A,et al. Type I Helicobacter pylorilipopolysaccharide stimulates toll-like receptor4and activates mitogen oxidase1in gastricpit cells. Infect Immun.2001Jul;69(7):4382-9.
38、Grebowska A, Rechciński T, Bak-Romaniszyn L,et al. Potential role of LPS in theoutcome of Helicobacter pylori related diseases. Pol J Microbiol.2006;55(1):25-30.39.Whittle BJ, Morschl E, Pozsár J,et al. Helicobacter pylori lipopolysaccharideprovokes iNOS-mediated acute systemic microvascular inflammatory responses in ratcardiac, hepatic, renal and pulmonary tissues. J Physiol Paris.2001Jan-Dec;95(1-6):257-9.
40、Libby P, Ridker P M, Maseri A, et al. Inflammation and Atherosclerosis.Circulation.2002;105:1135.
41、Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independentpredictor of the rate of increase in early carotid atherosclerosis. Circulation.2001Jul3;104(1):63-7.
42、Ridker PM, Danielson E, Fonseca FA,et al. Rosuvastatin to prevent vascular eventsin men and women with elevated C-reactive protein. N Engl J Med.2008Nov20;359(21):2195-207.
43、Corrado E, Rizzo M, Tantillo R.,et al. Markers of inflammation and infectioninfluence the outcome of patients with baseline asymptomatic carotid lesions: a5-yearfollow-up study. Stroke.2006Feb;37(2):482-6. Epub2005Dec22.
44、Jafarzadeh A, Hassanshahi GH, Nemati M, et al. Serum levels of high-sensitivityC-reactive protein (hs-CRP)in Helicobacter pylori-infected peptic ulcer patients and itsassociation with bacterial CagA virulence factor.Dig Dis Sci.2009Dec;54(12):2612-6.
45、El-Mashad N, El-Emshaty WM, Arfat MS,et al. Relation of Cag-A-positiveHelicobacter pylori strain and some inflammatory markers in patients with ischemic heartdiseases. Egypt J Immunol.2009;16(1):39-47.
46、Kebapcilar L, Bilgir O, Cetinkaya E, et al. The effect of Helicobacter pylorieradication on macrophage migration inhibitory factor, C-reactive protein and fetuin-alevels. Clinics (Sao Paulo).2010Jun;65(8):799-802.
47、Xiao Q, Mandal K, Schett G, et al. Association of Serum-Soluble Heat ShockProtein60With Carotid Atherosclerosis. Stroke.2005;36:2571.
48、Zhu J, Quyyumi AA, Rott D, et al. Antibodies to Human Heat-Shock Protein60Are Associated With the Presence and Severity of Coronary Artery Disease. Circulation.2001;103:1071.
49、Lenzi C, Palazzuoli A, Giordano N. H. pylori infection and systemic antibodies toCagA and heat shock protein60in patients with coronary heart disease. World JGastroenterol.2006Dec28;12(48):7815-20.
50、AndriéR, Braun P, Heinrich KW. Prevalence of intimal pathogen burden in acutecoronary syndromes. Z Kardiol.2003Aug;92(8):641-9.
51、王广,王育珊,陈星海.幽门螺杆菌HSP60与急性冠脉综合征及病变程度关系的研究.中国实验诊断学.2009,13(10):1397-8.
52、Okada T, Ayada K, Usui S, et al. Antibodies against heat shock protein60derivedfrom Helicobacter pylori: diagnostic implications in cardiovascular disease. J Autoimmun.2007Sep-Nov;29(2-3):106-15.
53、 Watanabe N, Ikeda U. Matrix metalloproteinases and atherosclerosis. CurrAtheroscler Rep.2004Mar;6(2):112-20.
54、Beaudeux JL, Giral P, Bruckert E. Matrix metalloproteinases, inflammation andatherosclerosis: therapeutic perspectives. Clin Chem Lab Med.2004Feb;42(2):121-31.
55、刘龙斌,郭航远,池菊芳.基质金属蛋白酶在动脉粥样硬化中的研究进展.中国全科医学,2009，12(7A):1232-4.
56、W gs ter D, Zhu C, Bj rkegren J, et al. MMP-2and MMP-9are prominent matrixmetalloproteinases during atherosclerosis development in the Ldlr-/-Apob100/100mouse.Int J Mol Med.2011Aug;28(2):247-53.
57、Mori N. Helicobacter pylori induces matrix metalloproteinase expression. NipponRinsho.2005Nov;63Suppl11:138-45.
58、Kundu P, Mukhopadhyay AK, Patra R, et al. Cag pathogenicity island-independentup-regulation of matrix metalloproteinases-9and-2secretion and expression in mice byHelicobacter pylori infection. J Biol Chem.2006Nov10;281(45):34651-62.
59、Rautelin HI, Oksanen AM, Veijola LI, Sipponen PI, Tervahartiala TI, Sorsa TA,Lauhio A.Enhanced systemic matrix metalloproteinase response in Helicobacter pylorigastritis.Ann Med.2009;41(3):208-15.
60、Kountouras J, Zavos C, Deretzi G, et al. Helicobacter pylori may be involved instroke pathophysiology by altering tumor necrosis factor-α and matrix metalloproteinases.Eur J Neurol.2011Jul;18(7).
61、Neta R, Sayers TJ, Oppenheim JJ. Relationship of TNF to interleukins. ImmunolSer.1992;56:499-566.
62、Sbarsi I, Falcone C, Boiocchi C, et al. Inflammation and atherosclerosis: the role ofTNF and TNF receptors polymorphisms in coronary artery disease. Int J ImmunopatholPharmacol.2007Jan-Mar;20(1):145-54.
63、Haddy N, Sass C, Droesch S, et al. IL-6, TNF-alpha and atherosclerosis riskindicators in a healthy family population: the STANISLAS cohort. Atherosclerosis.2003Oct;170(2):277-83.
64、Elkind MS, Cheng JF, Boden-Albala B. Tumor Necrosis Factor Receptor LevelsAre Associated With Carotid Atherosclerosis. Stroke.2002;33:31.
65、Elkind MS, Cheng J, Boden-Albala B, et al. Elevated white blood cell count andcarotid plaque thickness: the northern Manhattan stroke study. Stroke，2001，32:842.
66、Tufano MA，rossano f，catalanotti p，et al． Immunobiological Activitives ofHelicobacter Pylor Porins． Infect Immun.1994；62：1392.
67、Laurila A, Bloigu A, N yh S，et al． Chronic Chlamydia pneumoniae infection isassociated with a serum lipid profile known to be a risk factor for atherosclerosis.Arterioscler Thromb Vasc Biol.1997Nov;17(11):2910-3.
68、Adiloglu AK, Can R, Nazli C，et al． Ectasia and severe atherosclerosis:relationships with chlamydia pneumoniae, helicobacterpylori, and inflammatory markers.Tex Heart Inst J.2005;32(1):21-7.
69、Hamed SA, Amine NF, Galal GM，et al． Vascular risks and complications indiabetes mellitus: the role of helicobacter pylori infection. J Stroke Cerebrovasc Dis.2008Mar-Apr;17(2):86-94.
70、Cybulsky MI,Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyteadhesion molecule during atherogenesis. Science,1991,251(4995):788791.
71、 O'Brien KD, McDonald TO, Chait A, et al. Neovascular expression ofEselectin,intercellular adhesion molecule1in human atherosclerosis and their relation tointimal leukocyte content. Circulation,1996,93(4):672-82.
72、Hwang SJ; Ballantyne CM, Sharrett AR, et al. Circulating Adhesion MoleculesVCAM-1, ICAM-1, and E-selectin in Carotid Atherosclerosis and Incident Coronary HeartDisease Cases. Circulation.1997;96:4219-25.
73、Ameriso SF, Fridman EA, Leiguarda RC, et al. Detection of Helicobacter pylori inhuman carotid atherosclerotic plaques. Stroke.2001Feb;32(2):385-91.
74、Yoshida N, Kassai K, Murase H, et al. Effects of Helicobacter pylori water extracton expression of endothelial adhesion molecules. Can J Gastroenterol.2004Jun;18(6):387-91.
75、Oshima T, Ozono R, Yano Y, et al. Association of Helicobacter pylori infectionwith systemic inflammation and endothelial dysfunction in healthy male subjects. J AmColl Cardiol.2005Apr19;45(8):1219-22.
76、Schumacher A, Seljeflot I, Lerker d AB, et al. Does infection with Chlamydiapneumoniae and/or Helicobacter pylori increase the expression of endothelial cell adhesionmolecules in humans? Clin Microbiol Infect.2002Oct;8(10):654-61.
77、Liuba P, Pesonen E, Paakkari I, et al. Co-infection with Chlamydia pneumoniaeand Helicobacter pylori results in vascular endothelial dysfunction and enhanced VCAM-1expression in apoE-knockout mice. J Vasc Res.2003Mar-Apr;40(2):115-22.
78、Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis ofischemic stroke: a systematic review. Stroke.2008Oct;39(10):2902-9. Epub2008Jul24.
79、Cojocaru IM, Cojocaru M, Iliescu I, et al. Plasma myeloperoxidase levels inpatients with acute ischemic stroke. Rom J Intern Med.2010;48(1):101-4.
80、Wang CA, Liu YC, Du SY, et al. Helicobacter pylori neutrophil-activating proteinpromotes myeloperoxidase release from human neutrophils. Biochem Biophys ResCommun.2008Dec5;377(1):52-6.
81、Nazligul Y, Aslan M, Horoz M, et al. The effect on serum myeloperoxidase activityand oxidative status of eradication treatment in patients Helicobacter pylori infected. ClinBiochem.2011Jun;44(8-9):647-9.
82、Durrington PN, Mackness B, Mackness MI, et al. Paraoxonase and Atherosclerosis.Arteriosclerosis, Thrombosis, and Vascular Biology.2001;21:473-80.83、 Schmidt H, Schmidt R, Niederkorn K. Paraoxonase PON1PolymorphismLeu-Met54Is Associated With Carotid Atherosclerosis. Stroke.1998;29:2043-48.
84、Ranade K, Kirchgessner TG, Iakoubova OA, et al. Evaluation of the paraoxonasesas candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase1gene isassociated with increased risk of stroke. Stroke.2005Nov;36(11):2346-50.85、 Aslan M, Nazligul Y, Horoz M, et al. Serum paraoxonase-1activity inHelicobacter pylori infected subjects. Atherosclerosis.2008Jan;196(1):270-4.
86、Akbas HS, Basyigit S, Suleymanlar I, et al. The assessment of carotid intimamedia thickness and serum paraoxonase-1activity in Helicobacter pylori positive subjects.Lipids Health Dis.2010Aug30;9:92.
87、Páramo JA, Rodríguez JA, Orbe J, et al. Fibrinogen. An old hemostatic proteinwith a new function: non-invasive marker of subclinical atherosclerosis. Med Clin (Barc).2005May28;124(20):790-4.
88、Nazmi A, Diez-Roux AV, Jenny NS, et al. The influence of persistent pathogens oncirculating levels of inflammatory markers: a cross-sectional analysis from theMulti-Ethnic Study of Atherosclerosis. BMC Public Health.2010Nov17;10:706.
89、Pellicano R, Oliaro E, Fagoonee S, et al. Clinical and biochemical parametersrelated to cardiovascular disease after Helicobacter pylori eradication. Int Angiol.2009Dec;28(6):469-73.
90、Longo-Mbenza B, Nkondi Nsenga J, Vangu Ngoma D. Prevention of the metabolicsyndrome insulin resistance and the atherosclerotic diseases in Africans infected byHelicobacter pylori infection and treated by antibiotics. Int J Cardiol.2007Oct18;121(3):229-38.
91、B ger RH, Bode-B ger SM, Szuba A. Asymmetric dimethylarginine (ADMA): anovel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation.1998Nov3;98(18):1842-7.
92、Sibal L, Agarwal SC, Home PD, et al. The Role of Asymmetric Dimethylarginine(ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev.2010May;6(2):82-90.
93、Zhang Z, Zou YY, Li FJ, et al. Asymmetric dimethylarginine: A novel biomarker ofgastric mucosal injury? World J Gastroenterol.2011May7;17(17):2178-80.
94、F ndriks L, von Bothmer C, Johansson B, et al. Water extract of Helicobacterpylori inhibits duodenal mucosal alkaline secretion in anesthetized rats. Gastroenterology.1997Nov;113(5):1570-5.
95、Henriksn s J, Atuma C, Phillipson M, et al. Acute effects of Helicobacter pyloriextracts on gastric mucosal blood flow in the mouse. World J Gastroenterol.2009Jan14;15(2):219-25.
96、Marra M, Bonfigli AR, Bonazzi P, et al. Helicobacter. Asymptomatic Helicobacterpylori infection increases asymmetric dimethylarginine levels in healthy subjects.2005Dec;10(6):609-14.
97、Aydemir S, Eren H, Tekin IO, et al. Helicobacter pylori eradication lowers serumasymmetric dimethylarginine levels. Mediators Inflamm.2010;2010:685903.
98、Laurila A, Bloigu A, N yh S, et al. Association of Helicobacter pylori infectionwith elevated serum lipids. Atherosclerosis.1999Jan;142(1):207-10.
99、Satoh H, Saijo Y, Yoshioka E, et al. Helicobacter Pylori infection is a significantrisk for modified lipid profile in Japanese male subjects. J Atheroscler Thromb.2010Oct27;17(10):1041-8.
100、Matsui T. Helicobacter pylori and Arteriosclerosis. Gan To Kagaku Ryoho.2011Mar;38(3):365-9.
101、Corrado E, Novo S. H. Role of inflammation and infection in vascular disease.Acta Chir Belg.2005;105(6):567-79.
102、Polyzos SA, Kountouras J, Zavos C, et al. The association between Helicobacterpylori infection and insulin resistance: a systematic review. Helicobacter.2011Apr;16(2):79-88.
103、Manolakis AC, Tiaka EK, Kapsoritakis AN, et al. Increased fetuin A levels inHelicobacter pylori infection: a missing link between H. pylori and insulin resistance?Diabetologia.2011Feb;54(2):472-4.